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Factor V Leiden (FVL), the principal inherited cause of activated protein 
C resistance (APCR), has been linked to the failure of pregnancy with 
an increased risk of venous thrombosis, fetal loss and pre-eclampsia. 
Both venous thrombosis and pre-eclampsia are associated with 
inflammation. In particular pre-eclampsia is associated with a 
monocyte/macrophage Infiltration of the placental bed. That APCR, 
without FVL, (acquired APCR) may be a marker of thrombotic potential 
out-with pregnancy has been suggested by the association of venous 
thrombosis with the combined oral contraceptive pill and more recently 
by the association of venous thrombosis with a low activated protein C 
sensitivity ratio (the APC’.SR).
Changes in sensitivity to APC (assessed by the APC:SR) occur in normal 
pregnancy. The aetiology and significance of this phenomenon has not 
been fully characterised. In this thesis, the pattern of change in 
APC:SR in pregnancy was detailed in FVL negative subjects. The 
relationship of the APC:SR to other coagulation factors and thrombin 
generation was investigated. The significance of the APC:SR to the 
mother and the fetus was also examined. To investigate if a link (via 
thrombin) exists between the APC:SR and the inflammatory response, 
the inflammatory marker ICAM-1 was examined on the monocyte. The 
influence of thrombin on the expression of this marker was examined 
in vitro and the relationship between the APC:SR in pregnancy and 
ICAM-1 was examined ex vivo.
In a prospective study of 1046 pregnancies, the APC:SR at 7-15 weeks 
gestation showed a significant relationship with blood group and 
smoking, with higher APC:SRs observed in non-smokers and blood 
group 0  subjects. No significant relationship of APC:SR with body 
mass index, waist circumference, age, alcohol consumption, or family 
history of venous thrombosis or pregnancy-induced hypertension in a 
first degree relative was observed. In ~75% of pregnancies, a fall in 
APC:SR with Increasing gestation was seen. Those who showed a fall 
in APC:SR (i.e. an increase in APCR) with increasing gestation had 
higher absolute APC:SR values at 7-15 weeks gestation than those who 
did not show a fall. APC:SR values less than the reference range 
observed in non-pregnant females were seen in 38% of subjects in the 
third trimester of pregnancy (28 to 40 weeks gestation) in the absence 
of FVL or elevated ACAs. In subjects without elevated ACAs or FVL, 
the APC:SR showed a significant negative relationship with factor VIIIc, 
factor Vc, and a positive relationship with free protein S. The 
relationship to factor VIIIc is compatible with the association of APCR 
and Inflammatory disorders and with the association of non-blood 
group 0, higher factor VIIIc levels and venous thrombosis. The 
relationship with factor Vc is consistent with in vitro evidence that the 
APC:SR may be affected by factor V.
The fall in APC:SR with gestation paralleled the fall observed in the red 
cell count, haemoglobin and mean red cell volume. This appeared to 
be due to the effect of gestation on both, rather than an effect of the
m
APC:SR on the blood count It has been suggested that heterozygous 
carriage of FVL results in a reduction in blood loss at delivery. In FVL 
negative subjects, no relationship between pre-natal, peri-natal, or 
post-natal blood loss and APC:SR was observed. Similarly, in the small 
group of FVL positive subjects (n~37) observed no difference in pre­
natal, peri-natal, or post-natal blood loss was observed when 
compared with FVL negative subjects.
No significant relationship between the APC:SR and placental weight 
was observed, although in subjects with an APC:SR less than the 
reference range for non-pregnant females, smaller birth weights were 
noted. When birth weights were corrected by adjustment for parity, 
gestation at delivery and fetal sex and the influence of gestation on the 
APC:SR was minimised, no relationship between the APC:SR and birth 
weight was found. However significantly smaller birth weight centiles 
were observed in subjects in whom a fall in APC:SR with gestation 
occurred.
Significantly lower APC:SRs at 7-15 weeks were observed in subjects, 
normotensive at recruitment and with no past history of hypertension, 
who subsequently developed pregnancy-induced hypertension (PIH) or 
pre-eclampsia (PET) in the current pregnancy. This difference 
persisted for PIH when the analysis was restricted to primlgravid 
subjects. No relationship between the APC:SR at 27-34 weeks 
gestation and the occurrence of PIH or PET was noted. A 2 fold 
(C.I.95 1.1-3.6) increased risk of PIH and 3 fold increased risk of PET
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(C.I.95 1.2-8.0) in the current pregnancy was observed in those 
subjects in whom no decrease in APC:SR was seen when compared 
with those in whom the APC:SR did decrease from 7-15 to 27-34 
weeks. These results suggest that, in the absence of FVL, subjects 
with a lower APC:SR early in pregnancy do not increase resistance to 
APC with increasing gestation and are at a higher risk of development 
of PIH and PET. They also appear to have larger babies than those in 
whom an increase in APCR occurs. As lower APC:SRs are associated 
with venous thrombosis, and as a decrease in APC:SR occurs in the 
majority of pregnancies, this suggests that a higher APC:SR early in 
pregnancy and a fall in APC:SR with increasing gestation is a 
physiological response which mirrors fetal development. Individuals 
with a lower APC:SR early in pregnancy, do not become more resistant 
with increasing gestation and the (physiological) change in APC:SR 
does not occur. The response to APC appears to be set early in 
pregnancy and the sensitivity to APC may influence, or be influenced 
by, fetal development. The APC:SR, in the absence of FVL, does not, 
however, appear to predict fetal loss or neonatal death.
A significant inverse relationship between Fl+2 levels and APCiSR was 
observed, although this may reflect the influence of gestation on both 
variables. When the effect of increasing gestation was excluded, a 
significant inverse relationship between APC:SR and TAT concentration 
was observed at 28-32 weeks, suggesting that the APC:SR may reflect 
thrombin generation in vivo.
Monocyte ICAM-1 expression, as assessed by flow cytometry, was 
influenced in a specific dose-dependent fashion by human alpha 
thrombin and may therefore be a useful indicator of the link between 
the coagulation cascade, thrombin and the inflammatory response of 
this cell. In pregnancy, a significantly higher level of monocyte ICAM-1 
was observed when compared with non-COCP using female subjects. 
No significant relationship between ICAM-1 and gestation, parity or 
smoking was observed. In pregnant subjects, a significant positive 
relationship between monocyte ICAM-1 and plasma ICAM-1 was 
observed. This suggests that the monocyte contributes to plasma 
ICAM-1, which has been used widely as a marker of inflammation. A 
small but significant inverse relationship of both monocyte ICAM-1 and 
plasma ICAM-1 with APCiSR at 28-32 weeks gestation was noted. This 
suggests that in individuals with a normal pregnancy outcome the 
thrombin generation associated with the APCiSR at 28-32 weeks 
gestation is mirrored by the inflammatory response of the monocyte. 
However, as the monocyte has a significant, independent role in the 
activation of coagulation, it is conceivable that activated monocytes 
could also influence the sensitivity to APC in plasma by modulating the 
generation of factor Villa and factor Va.
A change In the sensitivity to APC appears to be a physiological 
response in pregnancy which mirrors fetal development. Whether 
acquired APCR has an independent role or simply reflects the sum total 
of contributing coagulation factors is unknown. However, the APC:SR
V I
reflects overall thrombin generation and may have a useful role In the 
prediction of disease states in pregnancy.
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Chapter 1
Introduction
1.1 In recent years there has been a substantial increase in knowledge linking 
pro-thrombotic tendencies with several adverse outcomes of pregnancy. This 
has been paralleled by an increased awareness of the central co-ordinating
role of vascular endothelium in inflammation, atherosclerosis and
haemostasis. The exact mechanism whereby pro-thrombotic (or
'thrombophilic’) tendencies lead to pregnancy failure is unknown. 
Thrombophilic abnormalities are associated with an increase in thrombin 
generation[1, 2]. As thrombin is both procoagulant and pro-inflammatory, 
this may result in stimulation of an inflammatory response from the 
endothelium and thrombosis of the placental vessels. Stimulation of an 
inflammatory response in the endothelium also results in secretion of pro­
adhesive molecules and cytokines and alteration of the anticoagulant protein 
C system on the endothelial surface[3-5].
1.2 Thrombin and the protein C/protein S system
1.2.1 The cascade of zymogen activation in the coagulation cascade leads to the
formation of thrombin (Figure 1.1). Thrombin is a serine protease which Is 
responsible for fibrin formation, platelet activation, activation of factor XIII 
(with cross-linking of the fibrin network) and the feedback activation of 
clotting factors Vc and VIIIc.
1.2.2 Thrombin has a direct action on the endothelium via a transmembrane 
thrombin receptor[6] (Figure 1.2). Via this interaction thrombin participates 
in tissue remodelling, wound repair, leukocyte chemotaxis, leukocyte
adhesion, vascular contraction and changes in vascular permeability 
(reviewed in[7]). This receptor is present on a variety of cells including 
platelets and monocytes[8]. On endothelial cells proteolytic cleavage of this 
receptor results in a wide variety of cellular responses including expression of 
leucocyte adhesive proteins such as P-selectin[9, 10] and intercellular 
adhesion molecule-1 (ICAM-1), the ligand for lymphocyte function antigen- 
1[11], on the endothelial surface. This response results in leukocyte 
adherence to the endothelium and further enhancement of the inflammatory 
response. Thus thrombin can participate in leukocyte chemotaxis and 
adherence (reviewed in[7]). Thrombin may also affect Immunological 
surveillance by stimulating T-cell activation and cytokine production[12]. The 
importance of the role of thrombin in the inflammatory response is confirmed 
by the consistent finding of thrombin generation accompanying leukocyte 
accumulation in several forms of inflammation[13, 14] and by the association 
of an inflammatory response with venous thrombosis[15, 16].
1.2.3 Thrombin also functions as an activator of the anticoagulant protein C 
pathway (Figures 1.3 and 1.4). Surface components and intracellular 
products of the endothelium play a significant role in the control of 
coagulation. In particular, the cell surface possesses a thrombin binding 
glycoprotein, thrombomodulin (TM)[17]. TM forms a high affinity 
(Kd=0.5nM) 1:1 complex with thrombin. Although thrombin may activate 
protein C directly, the complex formation accelerates the activation 20,000 
fold[17]. Formation of this complex directly inhibits the capacity of thrombin 
to cleave fibrinogen and activate platelets[ 17-20]. The proteolytic cleavage
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of protein C by thrombin results in the generation of the anticoagulant, 
activated protein C (APC). The complex of APC and plasma protein S 
assembles on membrane surfaces and inactivates activated coagulation 
factors, V and VIII (Figure 1.4). These interactions require the presence of 
Ca^ .^ It is also likely that the inactivate factor Vc acts as a cofactor in the 
inactivation of factor VIIIa[21].
1.2.4 Thrombin's effect on protein C is, however, complex. Acting via the 
endothelial thrombin receptor, thrombin produces an increase in TM RNA in 
the endothelium. However this does not result in an increase in TM
expression on the endothelial cell surface[22, 23]. Recently, another 
membrane-linked protein C receptor on the endothelial surface has been 
described. This endothelial protein C receptor (EPCR) also has a protein C 
activating function but has been found to bind protein C as well as APC with 
similar affinity[24]. The significance of this receptor is unknown, although
interestingly, it may also have a role In the inactivation of APC[25]. It has
been shown to have differing distribution in endothelial cell types, with a 
higher density found in large vessels rather than capillaries[26],
1.2.5 The protein C pathway appears to be critical to the control of the coagulation 
pathway as it is known that homozygous deficiency of protein C or protein S 
is associated with lethal thrombosis in neonates[27, 28] and gene deletion of 
TM is associated with embryonic lethality in mice[29]. Furthermore, inherited 
resistance of activated factor V to the effects of APC (Factor V Leiden-FVL) is 
the most frequently identified risk factor for a heritable thrombotic 
tendency[30]. The recent increase in understanding of the mechanism
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whereby acquired disorders, such as antiphospholipid syndrome[31, 32], 
hyperhomocysteinaemia[33] and dyslipidaemia[34, 35] interfere with the 
protein C/protein S system reinforces the central role of the protein C 
pathway in the control of haemostasis.
1.2.6 A strong link exists between the protein C pathway and inflammation. This is 
evident In disseminated intravascular coagulation. In primates, APC infusion 
prevents septic shock and death from otherwise lethal doses of bacteria[36] 
and inhibition of the action of the protein C pathway enhances the coagulant 
and inflammatory response to the bacteria[36, 37]. The mechanism whereby 
the protein C pathway influences the inflammatory process is unknown, 
although APC infusion in rodents prevents the septic shock response to 
endotoxin and diminishes cytokine elaboration, an action which may be 
mediated by an effect on monocytes[38, 39].
1.3 The function of ICAM-1
ICAM-1 results in leucoyte adherence via LFA-1. This will result in leukocyte 
recruitment to the inflammatory response. A soluble form of ICAM-1 is 
found in plasma. The physiological function of this soluble form is unknown, 
although it retains its ability to bind lymphocyte function antigen-1 (LFA- 
1)[40] and may have an immuno modulatory role. Soluble ICAM-1 has been 
used widely as a marker of endothelial activation in atherosclerosis[41-43], 
inflammation[44] and pregnancy disorders characterised by thrombosis and 
inflammation such as pre-eclampsia[45]. There is, however, little direct
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evidence confirming the relationship between soluble ICAM-1 and cellular 
expression[46]. ICAM-1 is expressed on a variety of cells in addition to 
endothelial cells[47-49] and, in-vitro, studies have shown that induction of 
membrane-bound ICAM-1 can be accompanied by an increase in shedding of 
soluble ICAM-1 from the surface of these cells[40, 50-52]. In the vascular 
system, the contribution that individual cell types make to the soluble plasma 
pool of ICAM-1, measured, in-vivo, is unknown.
1.4 The endothelium and coagulation
Aside from synthesis and expression of TM, the endothelium participates in 
the regulation of haemostasis and thrombosis by a number of other 
mechanisms (Figure 1.5). By synthesis of von-Willebrand factor and tissue 
factor the endothelium promotes platelet adhesion and triggers the 
coagulation cascade. The endothelium also regulates fibrinolysis by the 
synthesis and secretion of tissue plasminogen activator (tPA) and 
plasminogen activator inhibitor (PAI)(reviewed in[53]). The extracellular 
matrix around the endothelium, which contains heparans, enhances the 
activity of antithrombin[54]. Heparans also release tissue factor pathway 
inhibitor from its endothelial cell stores[55]. Thus the endothelium is pivotal 
to the regulation of coagulation, fibrinolysis and the endogenous 
anticoagulant system. Furthermore, the endothelium provides a link between 
the coagulation system and the inflammatory response. Clinical and 
experimental studies have shown that inflammation/infection is associated
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with enhanced production of inflammatory cytokines such as interleukin-1 
beta (IL-lp), interleukin-6 (IL-6) and tumour necrosis factor alpha (TNFa). 
Infusion of TNFa to normal humans induces a sustained activation of 
coagulation with increased turnover of thrombin evident for 6-12 hours after 
infusion[56]. In cell culture and animal experiments, TNFa elicits tissue 
factor expression on endothelial cells[57] and results in a significant increase 
in plasma TM despite an inhibitory effect on TM RNA transcription[4], 
translation[58] and expression on endothelial cells[59, 60]. Endotoxin, which 
has been utilised to model the inflammatory response in-vitro, also reduces 
TM expression and enhances tissue factor release from the endothelial 
surface[60]. In addition thrombin will promote expression of cell adhesion 
molecules which control leukocyte recruitment and activation at sites of 
inflammation.
1.5 The monocyte, inflammation and coagulation.
1.5.1 Monocytes have a central function in the inflammatory response and express 
a variety of adhesion molecules, including intercellular adhesion molecule-1 
(ICAM-1)[8, 61]. Like endothelial cells, monocytes possess thrombin 
receptors[62] and stimulation of monocytes with thrombin receptor agonist 
peptides has been shown to result in an increase in intracellular calcium[63]. 
Thrombin interacts with monocytes to enhance secretion of TNFa, 
interleukin-1 [64] and plasminogen activator inhibitor-2[65]. Although
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thrombin stimulates adhesion molecules on the endothelium, it is not known 
whether thrombin influences ICAM-1 expression on the monocyte.
1.5.2 Monocytes participate in the coagulation cascade by a variety of means 
including production of tissue factor[66], activation of coagulation factor 
X[67] and participation in the control of fibrinolysis[68]. Monocytes also 
possess TM[69] and a specific receptor for APC has been reported to occur 
on the surface of the cell[70]. Inflammatory mediators, such as TNFa, 
increase the expression of TM on the monocyte surface[38], but decrease its 
expression on the endothelial surface[60]. The increase in monocyte TM 
expression is accompanied by an increase in ICAM-1 expression on the cell 
surface[38],
1.6 Activated protein C resistance
Resistance to the anticoagulant effect of APC added in-vitro to plasma was 
first recognised as an important cause of familial thrombosis in 1993[71]. 
Depending on selection criteria. It is present in 20% to 70% of those 
individuals who have had a venous thrombotic event[72, 73]. In the vast 
majority of individuals with familial APC resistance the resistance is due to 
the presence of a point mutation Glycine->Arginine at position 1691 (G^A 
1691) in the gene coding for coagulation factor V (Factor V Leiden - 
FVL)[74]. This mutation is highly prevalent in European populations (2- 
7%)[75]. Screening for APC resistance (APCR) is commonly based on an 
activated partial thromboplastin test (APTT). In this test a ratio of the APTT
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in the presence and absence of added APC is obtained (i.e. APTT plus added 
APC/APTT minus added APC). This is designated as an 'APC sensitivity ratio' 
(APC:SR). A low APC:SR implies APCR. The significance of APCR occurring 
in the absence of the FVL mutation is unknown. Low ratios have been 
described in the latter stages of pregnancy[76], In subjects on oestrogen 
therapy[77] and with other variations in the factor V gene[78, 79]. 
Furthermore, the standard APTT-based assay is unreliable in the presence of 
antiphospholipid antibodies[80] or anticoagulant therapy[81]. Pre-dilution of 
patient plasma with factor V depleted plasma prior to APTT testing renders 
the test insensitive to anticoagulants or gestation and more specific for the 
FVL mutation[81, 82].
1.7 Acquired Activated Protein C Resistance
1.7.1 Although the importance of APCR in the absence of the FVL mutation is 
poorly understood, a number of published observations would suggest that 
APCR may be a potential marker of a prothrombotic tendency. A negative 
correlation between FVIIIc and APC:SR (a positive correlation between FVIIIc 
and APCR) was reported in 1996[83, 84]. Elevated FVIIIc levels, a common 
manifestation of inflammation, have been shown to be an independent risk 
factor for venous thrombosis[85]. This association of FVIIIc and thrombosis 
may be linked to blood group[85-87] In that non-blood group 0  subjects 
have higher FVIIIc levels and a higher incidence of venous thrombosis.
1 6
1.7.2 Both elevated anticardlolipin antibodies and the presence of a lupus inhibitor 
may be associated with a reduction In the APC:SR as measured by the 
classical APTT-based test[88/ 89]. Individuals with an APCR phenotype show 
a strong relationship between APCR and FVL carriage in those with 'weak' 
lupus inhibitor activity[88]. In contrast, those with strong lupus inhibitor 
activity show a weak association between APCR and FVL. The observation of 
an influence of anti Bz glycoprotein-1 antibodies on the APC:SR of normal 
plasmas suggest that antiphospholipid antibodies may have a direct effect on 
the inactivation of FVa[90] and result in APCR. Interestingly, in a subsequent 
small study, Aznar et al suggested that the degree of APCR associated with 
antiphospholipids may correlate with thrombotic risk[89].
1.7.3 In 1994 Vandenbrouke et al reported that subjects who are heterozygous for 
FVL and who use a combined oral contraceptive (COCP) have a 30 fold 
higher risk of development of thrombosis than non FVL, non-COCP users[91]. 
In keeping with a previous study[92], they also noted an approximately 4 
fold relative risk of venous thrombosis and use of COCPs in the absence of 
FVL. In 1994, Osterud et al noted that COCP use was associated with 
resistance to APC when assessed by an APTT-based method[93]. This 
finding was confirmed by Henkens et al[94] and Olivieri et al[77], who also 
reported that cessation of the COCP in 2 subjects, without FVL, resulted in 
normalisation of the APC:SR. These findings were not supported by 
Mathonnet et al[95] who found no difference In APC:SR between COCP and 
non-COCP users. In this study however, a significantly lower APTT (without 
APC) was observed in COCP users and one individual (1/34) of the control
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group was found to carry the FVL mutation. This would result in a significant 
reduction in the APCiSR "normal" range obtained and exclusion of FVL in all 
subjects has been recommended in the construction of "normal" pool 
material for analysis of the APC:SR[96].
1.7.4 Resistance to the effects of APC added in-vitro to plasma has also been 
assessed by the pattern of thrombin generation which occurs when piasma is 
stimulated by tissue factor (i.e. by activation of the extrinsic coagulation 
cascade)[97]. Using this technique Rosing et al have reported similar APCR 
in non FVL, COCP users to that observed in non-COCP users who are 
heterozygous for FVL. They suggest that acquired APCR may explain the 4 
fold increased risk of venous thrombosis observed in users of COCPs[98].
1.7.5 In a study of 20 pregnancies, a reduction in APC:SR with increasing gestation 
was reported in 1995[76]. However, only at 14-20 weeks gestation did the 
APC:SR correlate with the plasma level of FVIIIc. A reduction of APC:SR in 
pregnancy was confirmed by Mathonnet et al[95], who observed a lower 
APC:SR in 32 pregnant subjects at delivery, in comparison to control non­
pregnant, non-COCP using subjects and COCP users. The delivery APCiSR 
correlated with delivery levels of FVIIIc. Although a higher level of FVc was 
observed in comparison to control non-COCP and COCP-using subjects, no 
correlation with FVc and APC:SR was observed. Confirmation of a 
relationship between FVIIIc and APC:SR in early pregnancy was reported by 
Bokarewa et al In 1997[99]. No information was available regarding FVc. 
Interestingly, the standard deviation of the mean APC:SR in the third 
trimester was less than that observed post-partum and subjects with the
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lowest post-partum APC:SR values showed the least change during 
pregnancy. These observations would be consistent with tight control of the 
response to APC in pregnancy. As 57-76% of women develop an APC:SR 
less than non-pregnant reference ranges during pregnancy[76, 99], this is 
clearly a physiological adaptation. The significance of this adaptation is, 
however, unknown.
1.8 Heritable abnormalities of the protein C/protein S system
A number of heritable abnormalities of elements of the protein C pathway 
have been described.
1.8.1 Protein C deficiency
Heritable deficiency of protein C has been estimated to occur In 1 in 300 to 
500 of the population[100, 101]. In studies investigating blood donor 
populations, the majority of individuals identified biochemically or genetically 
are symptom free[100, 101]. Protein C deficiency has been classified into 
two types: Type 1, a quantitative reduction in functionally normal protein C 
and Type 2, a higher level of protein C antigen than activity. Type 2 
deficiency results from production of a functionally abnormal protein C 
molecule.
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1.8.2 Protein S deficiency
The prevalence of protein S deficiency in the general population has not been 
established in a large scale study of healthy individuals. Protein S is a 
vitamin K-dependent single chain glycoprotein. Plasma levels of protein S 
are dependent on age, sex[102], lipid levels, oestrogen[103] or oral 
anticoagulant usage. In plasma, approximately 60% of circulating protein S 
is bound to C4b binding protein. Only free protein S is able to function as a 
cofactor for protein C. Heterozygous protein S deficiency is a significant risk 
factor for thrombosis[104]. At present there is no unified classification of 
protein S deficiency. Three classes of protein S deficiency have been 
proposed: Type 1, a reduction in total and free protein S; Type 2, a reduction 
is protein S activity with normal free and bound antigen levels and Type 3, a 
reduction in free antigen and activity with a normal total protein S. In 1993 
Faioni reported[105] that some protein S functional assays give falsely low 
protein S activity assessments in the presence of FVL. This finding has 
subsequently been confirmed In other studies[106, 107]. There is currently, 
therefore, no universally accepted functional protein S assay.
1.8.3 Factor V Leiden
The presence of FVL can be detected directly by mutation analysis of DNA for 
the G-^A mutation at nucleotide position 1691 of the factor V gene. Recently 
a factor V gene polymorphism (the HR2 haplotype)[78] and another gene
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mutation (Arg306-»Thr, Factor V Cambridge) in factor V have been 
described[79]. These also result in an APCR phenotype, although the 
prevalence of these genetic variations is unknown.
1.8.4 Thrombomodulin
The glycoprotein TM is synthesised within endothelial cells and expressed on 
the endothelial surface. The gene encoding TM Is found on chromosome 
20[108, 109]. Although little evidence links genetic mutations of the TM 
gene with clinical thrombosis, in animal studies congenital absence of TM 
results in lethality in-utero[29]. An amino acid dimorphism in the TM gene at 
position 1418, which predicts an alanine or valine at position 455 in the TM 
molecule, has been associated with premature myocardial infarction[110], 
but has been reported to be neutral as regards the occurrence of venous 
thrombosis[lll]. The mechanism whereby this contributes to abnormal TM 
function or alters TM thrombin affinity is unknown and as yet, there is no 
information regarding the influence of this genetic variation on pregnancy 
outcome. TM expression is down-regulated by a number of influences on the 
endothelium including cytokines, endotoxin and hypoxia[112, 113]. Oxidant 
injury also results in a decrease in TM activity[114]. TM expression on 
endothelial cells is influenced by a number of inflammatory mediators 
including TNFa[4, 58-60] and endotoxin[60]. TM can also be shed from the 
endothelial surface by neutrophil elastase[115] and soluble TM (sTM) has
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been used as a marker of the effect of inflammation on the endothelium[116- 
118].
1.9 Haemostasis and endothelial function in normal pregnancy
1.9.1 Coagulation and the protein C/protein S system
Normal pregnancy is associated with changes In many coagulant and 
anticoagulant factors. By the end of the normal gestation there is a mean 
rise in the vitamin K dependent factors lie, VIIc and Xc[119]. In addition, a 
small increase in factor XIc and factor Vc has been reported[119], although 
this was not been confirmed in a subsequent study[120]. Protein C antigen 
and activity levels are not progressively affected by gestatlon[121, 122], 
although an increase in protein C activity has been reported at the beginning 
of the puerperium[123]. Normal pregnancy is associated with a progressive 
fall in free and total protein S antigen[119]. APC:SR, when assessed by the 
classical APTT-based test has been shown to fall with increasing 
gestation[76]. Modification of the test, by pre-dilution of patient plasma with 
coagulation factor V depleted plasma, results In an insensitivity of the test to 
the effects of pregnancy[124]. Antithrombin activity has consistently been 
reported to be unaffected by normal gestation[125-127].
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1.9.2 Thrombin generation
Enhanced thrombin generation may result from an increase in procoagulant 
factors[l], a decrease in circulating natural anticoagulants[l], from 
inflammation[128, 129] and from thrombosis itself. Thrombin formation has 
been assessed, ex-vivo, by the circulating levels of a number of marker 
proteins formed as a consequence of thrombin formation or inactivation. As 
prothrombin is cleaved by factor Xa to form thrombin, a fragment is released. 
This fragment is called prothrombin fragment 1+2 (Fl+2) and can be 
measured in plasma by an enzyme linked immunoabsorbent assay 
(ELISA)[130]. Thrombin formation can also be assessed by the circulating 
level of the complex that it forms with its principle inhibitor, antithrombin (the 
thrombin-antithrombin or TAT complex)[130].
An increase In TAT complex formation occurs in normal pregnancy[127, 131, 
132]. TAT complex levels higher than non-pregnant control values have 
been reported to be present in 50% of women during the first trimester with 
ail subjects showing elevated levels in the second and third trimesters[127]. 
A significant positive correlation between gestational stage and elevated 
Fl+2 has also been shown[133, 134], with leveis elevated beyond non­
pregnant subjects seen early in pregnancy[134]. These results show that 
activation of coagulation occurs in normal pregnancy. Delorme et al[135] 
have shown that pregnant plasma in in-vitro experiments is capable of more 
rapid and elevated generation of thrombin than non-pregnant plasma. This 
result, in combination with evidence of an increase in prothrombin activation
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and TAT complex formation, suggests that heightened thrombin generation 
may be a feature of normal pregnancy.
Fibrin formation is known to be essential for normal placental 
implantation[136, 137]. It is therefore plausible that the enhanced thrombin 
generation of pregnancy is stimulated by the placenta[138]. As thrombin has 
both procoaguiant and anticoagulant functions it is not clear whether the 
enhanced thrombin generation of pregnancy contributes to a pro-thrombotic 
state.
1.9.3 Protein C activation
As described above, protein C is activated by thrombin in the presence of TM. 
APC is known to be regulated by several inhibitors: protein C inhibitor-l[139], 
al-antitrypsin (also known as al-antiproteinase)[140], a2-antiplasmin. Cl 
esterase inhibitor[141] and a2-macroglobulin[142]. The recently described 
EPCR[5] may also have an inhibitory function on APC, although its role In 
protein C homeostasis is, as yet, unknown. It is possible to assess the 
activity of thrombin on protein C activation by measuring APC[143], by 
measuring the peptide released from protein C on activation[144] or by 
measuring complexes of APC with its inhibitor al-antitrypsln[140]. An 
increase in APC/al-antitrypsin in the third trimester to double the level 
observed in the first trimester has been reported to occur in normal 
pregnancy[145]. In this study APC/al-antitrypsin levels did not correlate
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with al-antitrypsin. This would be consistent with an increase in the 
activation of protein C, and therefore thrombin activity, with gestation.
1.9.4 Thrombomodulin
The influence of normal pregnancy on endothelial expression of TM is not 
known. Thrombin, via its endothelial receptor, is capable of down regulating 
TM expression on the endothelial surface[22, 23]. As with other indices of 
endothelial activation, plasma levels of sTM have been shown to increase 
progressively with gestation in normal pregnancies[146].
1.10 APC resistance and thrombin generation
A number of studies have shown that carriage of FVL is associated with an 
increase in the markers of thrombin generation[l, 2] similar to that seen in 
individuals with a past history of thrombosis. The effect of acquired APCR on 
thrombin generation has not been assessed. However, in the diagnosis of 
acquired APCR associated with COCP use Rosing et al have shown that 
plasma from 3''^  generation COCP users has greater potential to generate 
thrombin than non-COCP and 2"^  generation COCP users[98]. The 
relationship between this increase in thrombin potential and thrombin 
generated in-vivo is not known.
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1.11 The protein Ç/proteIn S system and pregnancy failure
l.ll.lThere  Is now a considerable body of evidence suggesting that inherited 
disorders such as FVL[147-149], protein C or protein S deficiency[148, 150- 
152] can lead to pregnancy failure and pregnancy-related thrombosis. In 
particular, recent investigations have concentrated on the potential role of 
these pro-thrombotic abnormalities in the occurrence of pre-eclampsia, fetal 
loss and the protection of the blood count in pregnancy.
1.11.2Pre-eclampsia
Pre-eclampsia is a multi-system disorder which presents with proteinuria and 
hypertension. It is characterised by widespread vascular endothelial damage 
and dysfunction which is associated with failure of trophoblastic invasion of 
the spiral arteries of the placenta[153]. A number of the spiral arteries of 
the developing placenta are occluded by fibrin deposits and surrounded by 
foam cell infiltration[154, 155], a feature similar to atherosclerosis and 
termed 'acute atherosisL
Inflammation
Endothelial dysfunction is common to all the pathological features of pre- 
eclampsia[156]. It Is unclear, however, what triggers this endothelial 
disturbance, although abnormalities of platelets[157, 158], endothelial
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function[159-161], and neutrophil activation have all been implicated in the 
pathophysiology[162, 163]. Several studies have shown that the serum of 
patients with pre-eclampsia have increased levels of circulating VCAM-1 
(vascular cell adhesion molecule-l)[45, 156] and ICAM-1 (intercellular 
adhesion molecule-l)[45]. These integrins are involved in the adherence of 
leucocytes to the endothelium and an increase in the expression of ICAM-1 
and V-CAM-1 may result in an increase in leucocyte adherence[164, 165]. 
The cause of the increase in expression and shedding of CAMs is not known, 
but various cytokines including interleukins[166] and TNFa[167] upregulate 
the expression of cellular adhesion molecules on endothelial cells. Elevated 
concentrations of both TNFa[168] and interleukin-6[169] have been reported 
in the maternal plasma and amniotic fluid of women with severe pre­
eclampsia. An increase in mRNA expression for TNFa has been found in pre­
eclamptic placentas[170]. Although the source of its production is unknown, 
TNFa may be produced by macrophages present in the placental stroma. In 
addition to the upregulation of CAM expression on endothelial cells[167], 
TNFa has been shown, in-vitro, to directly impair vascular endothelial 
function by activating neutrophils directly to adhere to endothelial cells[171]. 
Thus the monocyte/macrophage system appears to be integral to the 
necrotlsing arteriopathy of pre-eclampsia which is characterised by 
accumulation of lipid-laden macrophages and mononuclear perivascular 
infiltration[155].
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Coagulation
It has been known for many years that pre-eclampsia is associated with 
activation of the coagulation and fibrinolytic systems. In those subjects with 
hypertensive disorders of pregnancy, a number of changes in the coagulation 
system similar to those described in chronic disseminated intravascular 
coagulation have been reported. These include, a reduction in antithrombin 
activity, plasminogen level and platelet count and an increase in fibrin 
degradation products[172, 173]. Both Reinthaller et al[132] and Halligan et 
al[174] have shown that high TAT complex levels (higher than those found in 
normal pregnancies) are seen in individuals with pre-eclampsia. As 
antithrombin levels appear unaffected by gestation and as antithrombin may 
even be consumed in pregnancy-induced hypertension[175], these results 
suggest that exaggerated thrombin generation is a feature of gestational 
hypertension. The overall thrombotic potential of this increase in thrombin 
activity in pre-eclampsia is not clear, as an increase in protein C activation 
has also been reported[145]. Coagulation markers of endothelial activation, 
such as von-Willebrand factor[176], fibronectin[174] and plasma TM[177- 
179] are elevated in pre-eclampsia and, along with antithrombin 
activity[180], may have a role as predictive markers for the disease. In two 
studies pre-eclampsia has been associated with an elevation of plasminogen 
activator inhibitor-1 (PAI-1) and a reduction in plasminogen activator 
inhibitor-2 (PAI-2) levels when compared with normotensive 
pregnancies[174, 181]. The mechanism and significance of these
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observations remains speculative at present. It is likely that these changes in 
coagulation activation and fibrinolysis are, however, a secondary 
phenomenon rather than the primary initiators of hypertension in pregnancy.
The protein C pathway
APCR and FVL
Studies of the impact of APCR on the incidence of pre-eclampsia have not, in 
the main, distinguished between FVL and other causes of APCR. Two case 
reports have linked the heterozygous inheritance of the FVL gene with both 
pre-eclampsia[182] and the HELLP (haemolysis, elevated liver enzymes and 
low platelet count) syndrome[183]. In subjects with a history of pre­
eclampsia, a 2 fold higher carrier rate for FVL has been described[184] and a 
higher rate of occurrence of APCR in pre-eclamptic women is also reported by 
Dekker et al[152]. In this study no assessment of FVL status was made and 
although patients were assessed for the presence of a lupus inhibitor and 
anticardiolipin antibodies. It is not clear if subjects positive for these 
abnormalities (29.4%) were excluded from the APC:SR assessment. Lindoff 
also describes an odds ratio of 2.5 (C.I.95 0.9-9) for prevalence of FVL in 50 
subjects with pre-eclampsia versus controls sampled more than 6 months 
after delivery[185]. As with the paper by Dekker no distinction is made 
between APCR and the presence of the FVL mutation. A 5 fold relative risk 
(C.I.951.3-18.3) of Inheritance of FVL is also reported in a larger case control
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study of pre-eclampsia and FVL[186]. In a more recent study, APC:SR and 
FVL were assessed together in 279 subjects with a history of pre-eclampsia, 
eclampsia or HELLP syndrome. All subjects were sampled at least 10 weeks 
after pregnancy. Interestingly, an APC:SR lower than local reference range 
was found in 11.1% of subjects with these disorders but in none of the 
controls. From this study it appears that only 6% of patients of subjects with 
these disorders were positive for FVL. The aetiology of the APCR in the 
remainder is not stated. At 10 weeks post-pa rtum the acquired APCR 
associated with normal pregnancy[76] is likely to have resolved and whether 
these results point to an independent role for acquired APCR in the 
development of pre-eclampsia remains to be confirmed.
Protein C and protein S deficiencv
In 1987 a case study suggested an association between inherited protein C 
deficiency and the development of pre-eclampsia[187]. In a subsequent 
study by Dekker, 24% of subjects with severe early-onset pre-eclampsia had 
evidence of protein S deficiency[152]. However only 1 of the 85 patients 
tested showed evidence of protein C deficiency.
1.11.3Fetal loss
A single spontaneous fetal loss occurs in 14-19% of clinically recognised 
pregnancies[188], whereas three or more consecutive pregnancies losses are
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uncommon and occur in oniy 0.4-0.8% of women[189]. Early pregnancy 
losses are much more common than late pregnancy loss (6.1/1000 total 
births) and a variety of other endocrine, infectious and mechanical variables 
should be considered before a link between thrombophilia and fetal loss can 
be made. In the study of fetal loss and thrombophilia, two approaches 
predominate: case/control studies where subjects with fetal loss represent 
the cases, and case/control studies where subjects with inherited 
thrombophilia represent cases. The results of these two approaches may not 
be directly comparable. Furthermore it is likely that different thrombophilic 
factors may not have an identical influence on the gestation at which fetal 
loss occurs. Fetal loss may be associated with placental insufficiency and 
infarction[190] and placental infarction has been reported in association with 
abnormalities of the protein C/protein S system[191], abnormalities of 
homocysteine metabolism[192], with the presence of lupus inhibitors[193] 
and, in animal studies, with the absence of TM[29].
FVL and APCR
A number of case reports have suggested that maternal carriage of FVL or 
APCR is associated with fetal loss[182, 194, 195]. That APCR influences 
recurrent later rather than early pregnancy loss was suggested by Rai et 
al[196, 197] and subsequent studies have confirmed that there is no 
significant excess of inheritance of FVL in women with recurrent 1st trimester 
miscarriages[198-200] or fetal loss before 28 weeks gestation[148]. A
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relative risk of stillbirth with FVL of 2 (C.I.95 0.5-7.7)[148] and a relative risk 
of FVL inheritance and recurrent late pregnancy loss of 4.39 (C.I.95 1.3- 
14.7)[201] have been reported. Interestingly, one study has also suggested 
that fetal carriage of FVL may influence fetal loss and placental 
infarction[191], but as yet, there is little evidence that paternal FVL 
influences fetal outcome.
Protein C and Protein S
Two case reports in 1987 reported extensive placental infarction in 
association with third trimester intrauterine death and protein C 
deficiency[187, 202]. Subsequently conflicting family based studies have 
shown no[150], or a 2.5 relative risk[151] of fetal loss in subjects with 
protein C deficiency. Results from a large cohort of patients with hereditary 
thrombophilia (EPCOT) observed odds ratios of 1.4 and 2.3 for miscarriage 
(fetal loss less than 28 weeks) and stillbirth (fetal loss greater than 28 weeks) 
respectively in subjects with protein C deficiency[148]. The overall results of 
this study also suggest that heritable thrombophilia may have a greater 
impact in later than early pregnancy loss. Like protein C deficiency, protein S 
deficiency was also associated with a higher relative risk of stillbirth than 
miscarriage (O.R. 3.3 vs 1.2). This is in keeping with the positive risk of fetal 
loss with protein S deficiency previousiy reported (relative risk of fetal loss 
1.5)[151] and In keeping with the absence of protein C or S deficiency in 522 
subjects with more than three 1st trimester miscarriages[200].
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1.12 Blood loss in pregnancy and FVL
As the FVL mutation has a restricted distribution to individuals of European 
descent it has been suggested that the mutation has a single origin[203] and 
it has been suggested that the mutation was present in the first Europeans 
around 30-40,000 years ago[204]. This persistence in the population at a 
relatively high frequency may relate to an absence of effect on reproductive 
fitness despite its possible association with an increased relative risk of fetal 
loss. It has also been speculated that the persistence of the mutation may 
indicate a beneficial effect to the carrier. The most obvious potential 
advantage of an Increase in thrombotic potential would be in the reduction of 
blood loss and the protection of red cell and haemoglobin levels. This 
hypothesis has been examined in pregnancy in a single study[205] which 
showed a significantly reduced risk of intrapartum bleeding episodes and 
better preservation of the post-partum haemoglobin levels in FVL 
heterozygote subjects when compared to the non-FVL pregnant subjects. 
The estimation of blood loss in this study was highly subjective and it is likely 
that the changes in blood volume and differences in the type of delivery have 
a greater effect on post-partum haemoglobin measurements than FVL.
1.13 Summary of proposed investigation
1.13.1AS yet, acquired APCR of pregnancy has only been examined in small studies 
and there is no consistent information regarding the aetiology or prevalence
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of this phenomenon. Furthermore the clinical significance of this 
physiological adaptation as regards the outcome of pregnancy for the mother 
and the fetus has not been investigated. Thrombin generation is the 
presumed mechanism whereby heritable thrombophilia results in failure of 
pregnancy and thrombosis and in a variety of clinical circumstances thrombin 
generation is closely linked to the inflammatory response. Modulation of the 
inflammatory response occurs in normal pregnancy[146, 206] and a 
heightened inflammatory response Is observed in pregnancy disorders such 
as pre-eclampsia. Pre-eclampsia is characterised by acute atherosis which 
associated with monocyte/macrophage infiltration of the placenta (reviewed 
in[207]). The relationship of acquired APCR in pregnancy with thrombin 
generation and inflammation is unknown.
1.13.2It is proposed to examine
• the change in APC:SR in pregnancy and to determine the influence of
other coagulation factors on the APC response.
• the relationship between acquired APCR and markers of thrombin
generation.
• the significance of the APC response, in the absence of FVL, to fetal
growth.
• the relationship of acquired APCR with blood loss, changes in the
blood count and occurrence of maternal hypertension.
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To further investigate the link between thrombin, acquired APCR and
inflammation it is proposed
• to examine the response of an inflammatory marker (the adhesion
molecule ICAM-1) on the monocyte to thrombin in-vitro to determine if 
this has potential as a marker of thrombin's influence on monocyte 
function.
• to determine the relationship between monocyte ICAM-1 and plasma
ICAM-1 in pregnancy.
• to determine if the APCR of pregnancy is related to monocyte ICAM-1
and plasma ICAM-1 in vivo.
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Figure 1.1 The Coagulation Cascade
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Legend The activation of the coagulation factors with cofactors phospholipid (PL) and C a++ (Ca). 
Pre-kailikrein (PK) and high molecular weight kinlnogen (HK) is shown. The result of this cascade is 
the generation of thrombin, which is pivotal in fibrin formation, platelet/endothelial activation, fibrin 
stabilisation as well as the anticoagulant functions outlined in Figure 1.4.
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Figure 1.2 The interaction of thrombin with the endothelium
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Legend Thrombin (T) from the coagulation cascade interacts with a specific transmembrane 
receptor (T RECEPTOR). This results in a rise in intracellular Ca and an increase in ICAM-1, 
endothelin-1 (ET-1), interleukin-1 (IL -1), thrombomodulin (TM) and E-selectin (E-SEL) mRNA. 
This is accompanied by an increase in the release of P selectin (PSEL) and von-Willebrand factor 
(vW) from endothelial stores and an increase in ICAM-1 expression on the endothelial surface. 
This results in leukocyte adherence to the endothelium. The resultant inflammatory response 
may be associated with pre-eclampsia (PET) and fetal growth retardation (lUGR).
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Figure 1.3 The Interaction of the protein C/proteIn S system
with the endothelium
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Legend The generation of thrombin (T) from the coagulation cascade is shown. T  generation 
depends on the availability of activated factors V (Va) and V III (V illa ). FVL, APCR, AT protein C 
and S and lupus Inhibitors have a positive effect on T  generation. T  interacts with protein C (PC) 
and thrombomodulin (TM) to activate PC to activated PC (aPC). T  also activates fibrinogen (F lc) 
to fibrin. The source of prothrombin (PT) fragment 1+2 (F l+ 2 ) and thrombin-antithrombin 
(TAT) complexes is shown. The reported influence of Inflammation via TNF alpha (TNF a) and 
interleukin-1 (IL-1) on the system is also shown. Inflammation may also release TM from the 
endothelium (sTM).
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Figure 1.4 The protein cyprotein S system
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Legend Thrombin (T) interacts with thrombomodulin (TM) on the endothelial surface.
This alters the specificity of thrombin so that it activates PC to activated PC (APC). PC and 
APC interact with the endothelial surface via phospholipid and may also bind to the endothelial 
PC receptor (EPCR). The cofactor protein S (S), along with APC inactivates activated factor V 
(Va) to inactivated factor V (Vi). By a similar mechanism APC also inactivates factor V illa .
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Figure 1.5 The endothelium and coagulation
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Legend A = the vessel wall, B = the endothelium and C = the vessel lumen. SM = smooth 
muscle, COLL ~ collagen and SEN = subendothelial microfibrils. The endothelium contributes 
to platelet aggregation by synthesis and release of von Willebrand Factor (vWF) and 
thrombospondin. This is inhibited by nitric oxide (NO) and prostacyclin (PGI2). The 
endothelium participates in fibrinolysis via endothelin (ET), tissue plasminogen activator and 
plasminogen activator inhibitors. Via antithrombin (AT), tissue factor pathway inhibitor 
(TFPI), protein S, and heparans as well as protein C activation, the endothelium provides 
anticoagulant functions. The effect of these substances on platelet adhesion, vasodilatation 
and vasoconstriction is also shown.
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Chapter 2
Activated protein C sensitivity, protein C, protein S and coagulation
in normal pregnancy
41
2.1 Pregnancy is associated with significant changes in haemostasis. Over the 
last decade a number of studies have implicated the haemostatic mechanism 
with the occurrence of maternal and fetal disorders such as thrombosis[150, 
208], pre-eclampsia [133, 152, 183], fetal loss[148] and recurrent
miscarriage[197]. As outlined in Chapter 1, recent interest has focused on 
inherited resistance to the anticoagulant effect of ARC added in-vitro to 
plasma[71]. Two small studies have suggested that ARC resistance, 
occurring in the absence of FVL, may be a feature of normal pregnancy 
[76,95]. However the prevalence, aetiology and significance of activated 
protein C resistance occurring in the absence of the FVL mutation remains 
unclear.
In this chapter, systematic information on a range of haemostatic parameters 
in normal pregnancy and the early puerperium is presented. A study 
detailing the effect of gestation on ARC response assessed by the original 
unmodified ARTT-based assay and an ARTT-based assay modified by pre- 
dilution of subject samples with factor V depleted plasma[209] was carried 
out. The frequency of acquired ARCR in normal pregnancy was determined 
and the changes in components of the protein C/protein S system which may 
contribute to alterations in ARC response were investigated.
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2.2 Materials and methods
2.2.1 Subjects
A prospective, cross-sectional study of women during normal pregnancy was 
carried out. 239 healthy women attending a routine antenatal clinic at 
Glasgow Royal Maternity Hospital were entered into the study. Subjects had 
no previous history of hypertension or recurrent miscarriage, no significant 
medical disorder and no personal or family history of thrombosis. The study 
was approved by the hospital ethical committee and written consent was 
obtained from all participating subjects. Each subject was sampled on a 
single occasion. Samples were obtained at all stages of gestation and at 
three days post-partum (3PN) by venepuncture from the antecubital vein and 
anticoagulated in 1/10 volume of 0.105M sodium citrate. Following delivery, 
patient case records were re-examined to confirm that all pregnancies 
remained uncomplicated. Pregnancy duration, blood pressure, urinalysis 
results, blood loss at delivery, placental and fetal weight were recorded.
2.2.2 Assay Methodology
Immediately after collection, samples were stored at 4°C for less than one 
hour, prior to double centrifugation at 3000G for 12 minutes. The resultant 
platelet poor plasma was stored at -70°C until analysis.
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The APCR was assessed using the Coatest APC resistance kit (Chromogenix 
AB, Sweden), using the automated coagulometer ACL 3000 and expressed as 
an APC sensitivity ratio (APC:SR). The Coatest APC resistance kit is an 
Activated Partial Thromboplastin (APTT) based test which provides a semi- 
quantitative determination of the human response to APC. Subject plasma is 
incubated with the APTT reagent (a mixture of purified phospholipids with 
colloidal silica as a contact activator) at 37°C. Coagulation is triggered by the 
addition of calcium chloride (CaClz) in the absence and presence of APC and 
the time for clot (fibrin) formation is recorded. A ratio of clot time with APC 
to clot time without APC is calculated. This is the APC:SR.
The ACL 3000 uses an optical detection method to detect fibrin formation. 
The light source is a light emitting diode (wavelength 660 nm). The light ray 
is directed to the measuring cuvette by means of an optic fibre system. The 
scattered light is read at 90° with respect to the light source by a solid state 
detector. Fibrin formation is detected by the change in light scatter 
associated with the formation of fibrin clot.
The Modified APC:SR (mAPC:SR) was measured using Coatest APC resistance 
kit (Chromogenix AB, Sweden). In this test the subject plasma is pre­
incubated with factor V depleted plasma in a dilution of 1 part subject plasma 
to 4 parts factor V depleted plasma (Chromogenix AB, Sweden). The APC 
response of the mixture Is obtained as above. References ranges for APCiSR 
and mAPC:SR were obtained from the analysis of plasma obtained from 25 
healthy, non-pregnant, non-COCP using females.
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Protein C (PC) activity was assessed using an automated amidolytic assay 
using Immunochrom Protac Activation kit (Immuno, Austria). The test is 
based on the chromogenic substrate PCa-1 for the enzyme activated PC. PC 
in the test sample is activated with Protac®, an extract of the venom of the 
snake Agkistrodon contortix. The resultant activated PC then reacts directly 
with the substrate PCa-1 to release the chromogen p-nitroaniline. The level 
of p-nitroaniline is directly proportional to the level of PC.
Total protein S (PST) and free protein S (PSF) antigen were measured using 
an enzyme linked immunoassay (ELISA, Dako Ltd, UK). In plasma, 
approximately 60% of circulating protein S is bound to C4b binding protein. 
Only free protein S is able to function as a cofactor for protein C. 
Polyethylene glycol 8000 (PEG 8000) is used to precipitate the C4b-binding 
protein-protein S complex from the plasma leaving free protein S in the 
supernatant. The method allows the simultaneous measurement of PSF and 
PST by ELISA using anti-protein S IgG antibody as a capture antibody and 
the same antibody, linked to horse radish peroxidase, as the detection 
antibody.
IgG and IgM anticardiolipin antibody (ACA) assays were performed using 
sandwich ELISAs (Cambridge Life Sciences, UK). These employ antigen 
(cardiolipin) coated micropins. The pins are immersed into wells containing 
subject or reference plasma. Any antibody present will bind to the pin 
surface. The pins are then dipped into wells containing anti-IgG-peroxidase 
or anti-IgM-peroxidase conjugate which will bind to any captured antibody. 
Unbound antibody is removed by a washing stage. The pins are then dipped
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into wells containing a colourless substrate. The intensity of yellow colour 
formed from the reaction Is proportional to the concentration of 
anticardiolipin antibody bound in the first incubation.
Fl+2 was assessed by ELISA CEnzygnost Fl+2 micro', Behring, 
Germany)[210]. This ELISA is based on a sandwich principle. During the 
first incubation, Fl+2 antigen in the sample binds to anti-Fl+2 antibodies 
fixed to the surface of the micro-titration plate. The plate is then washed. 
Peroxidase-conjugated antibodies are added and, in the second incubation, 
bind to Fl+2. A subsequent wash step removes free peroxidase-conjugated 
antibodies. Quantification of bound antibody is determined photometrically 
from the reaction with hydrogen peroxide.
Antithrombin activity (AT) was measured using a fully automated amidolytic 
method CAntithrombin I I I  kif, Boehringer-Mannheim, Germany). The test 
principle is that antithrombin in test plasma is exposed to heparin in the test 
kit. An excess of thrombin is added. Available thrombin in the resultant 
solution converts the substrate Tos-Gly-Pro-Arg-pNA to Tos-Gly-Pro-Arg-OH 
and p-nitroanaline. The level of p-nitroaniline derived from the subject 
plasma is subtracted from that derived from a mixture of excess thrombin 
and Tos-Gly-Pro-Arg-pNA alone. This figure is converted to lU/ml of 
antithrombin.
FVL is identified in DIMA isolated from peripheral blood leucocytes. The G-+A 
1691 mutation disrupts a restriction enzyme site on the DNA. The 
polymerase chain reaction is used to amplify the DNA spanning the 
nucleotide change (147 base pairs) and the amplified product is cut using the
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enzyme Mnl 1. The products of the reaction are electrophoresed and 
visualised on 2.5% agarose gel.
Fibrinogen activity level (FIc) was determined by Clauss assay (Organon 
Teknika Corporation, UK). Prothrombin, factor V, and factor X coagulant 
activities (c) were determined by automated prothrombin time (PT) clotting 
assays using the relevant deficient-plasma substrates (Instrumentation 
Laboratory, UK). Factor VIII, IX XI, and XII coagulant activities (c) were 
assessed by automated activated partial thromboplastin time (APTT) assays 
using the relevant deficient-plasma substrates (Diagnostic Reagents Ltd [VIII, 
IX]; Instrumentation Laboratory, UK [XI, XII]) on an ACL 3000 coagulometer. 
IL-Test™ calibration plasma, (calibrated against the 1st International 
Standard Plasma-84/665, Instrument Laboratory, UK) was used as reference 
plasma in the prothrombin, FIXc and FXc assays and Diagen Normal 
Reference Control Plasma (calibrated against the 3rd International standard 
plasma-91/666, Diagnostics Reagents Ltd, UK) as reference plasma for the 
FVIIIc assay. Von-Willebrand factor Antigen (vWF Ag) level and Von- 
Willebrand Ristocetin Cofactor Antigen (vWF Ricof) levels were determined by 
ELISA using double-antibody 'sandwich' techniques (Dako Ltd, UK and Shield 
Diagnostics, UK).
2.2.3 Statistical Analysis
Results during pregnancy were divided into gestational age periods of 6-11, 
12-16, 17-23, 24-28, 29-35, 36-40 weeks and three days post-natal (3PN).
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Mean and 2 standard deviation (2 SD) normal ranges were produced for each 
period. For non-para metric data, data were logarithmically transformed prior 
to statistical analyses. Normal ranges were derived for APC:SR and mAPC:SR 
after the exclusion of subjects with elevated anticardiolipin activity or the 
G^A 1691 mutation. Where the data had been transformed, the normal 
ranges for the transformed data were transformed back in order to provide 
normal ranges for the original (untransformed) data. In those subjects with 
no evidence of increased anticardiolipin activity or the G^A 1691 mutation, 
linear regression analyses were carried out to compare changes in APC:SR, 
factor Vc, factor VIIIc, free protein S antigen and haematocrit with gestation. 
Linear regression analyses were also used to compare APC:SR with factor Vc, 
factor VIIIc and free protein S antigen levels during pregnancy and the 
puerperium. Analysis of variance was used to compare parameters at 
different gestations. Statistical analyses were carried out using Minitab® for 
Windows® Release 11 statistical software (Minitab Inc, USA).
2.3 Results
2.3.1 The change in coagulation parameters with gestation
Increasing concentrations of factor VIIIc (from 107iu/dl, SD 79 at 6-11 
weeks to 192iu/dl, SD 138 at 3 days post-natal) were seen as pregnancy 
advanced, with levels remaining elevated at 3 days post-natal (Table 2.1 and 
Figure. 2.1). Factor Vc rose after 16 weeks gestation (from lOlu/dl, SD 61
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at 12-16 weeks to 141u/dl, SD 70 at 3 days post-natal) and elevated levels 
persisted to 3 days post-natal (Table 2.1 and Figure 2.1). AT (Table 2.1) and 
PC (Table 2.1 and Figure 2.1) levels showed no relationship to increasing 
gestation, although an increase in protein C activity was seen at 3PN (Table 
2,1: analysis of variance of 3PN and 36-40 week values, p=0.0001). PST and 
PSF fell progressively through pregnancy (Table 2.1 and Figure 2.1). A fall in 
APC:SR was observed with increasing gestation (Figure 2.2, Linear regression 
R^=13%, t=-4.00, p<0.001). mAPC:SR showed no significant change with 
increasing gestation (Table 2.1 and Figure 2.2). A significant rise in Fl+2 
was noted when 12-16 week and 24-28 week values were compared (Table 
2.1: analysis of variance of 12-16 week and 24-28 week values, p=0.006). F 
1+2 levels remained elevated at 3PN (Table 2.1). Summary data for other 
factors are shown in Table 2.1.
2.3.2 FVL and anticardiolipin antibody positive subjects
Six individuals of 239 were heterozygous for the FVL mutation. All six 
subjects had a normal gestation and uncomplicated delivery at term. In 
these subjects there was no observed difference in Fl+2 in comparison with 
subjects without the FVL mutation. A further seven individuals of 239 (2.9%) 
showed levels of ACAs beyond 2 SD above the mean for the gestational 
period of the sample. Only one subject with elevated ACAs had an APC:SR 
less than 2.6 (APC:SR=2.1). All seven subjects had a normal gestation and
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uncomplicated delivery at term. In these subjects there was no observed 
difference in F 1+2 in comparison with subjects without elevated ACAs.
2.3.3 Relationship of FVIIIc, FVc, protein S with acquired APCR
APC:SRs of less than 2.6 (local non-pregnant female reference range: 2.6- 
4.5) were seen in 38% (22/58) of subjects in the third trimester of pregnancy 
(28 to 40 weeks gestation) in the absence of the FVL mutation or elevated 
ACAs. These women were defined as having acquired APCR.
In those subjects without elevated ACAs or FVL (n=226), regression analysis 
revealed a significant negative relationship between factor VIIIc (linear 
regression R^=3.7%, t=-2.81, p=0.005), factor Vc (linear regression 
R^=5.6%, t=-3.45, p=0.001), and a positive relationship of PSF (linear 
regression R^-6.8%, t=4.09, p=0.001) with APC:SR. No correlation of 
APC:SR with haematocrit was observed (data not shown, p>0.05). Previous
studies have demonstrated that APC:SR in non-pregnant subjects is
unaffected by factor Vc at levels of 12.5% to 100%[211, 212] but elevation
of factor Vc beyond 100% of 'normal' is associated with a significant
reduction in APC:SR[213]. To minimise the effect of factor Vc on the 
observed relationship between FVIIIc and APC:SR, samples with factor Vc 
values greater than/or equal to 120 u/dl were excluded from the analysis. 
The mean factor Vc level for the whole period of gestation was 120 u/dl and 
as factor V rose throughout gestation, this value was chosen to facilitate 
comparison with previous studies in non-pregnant subjects[211-213]. A
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significant relationship was observed between factor VIIIc and APC:SR in the 
106 subjects who had a factor Vc less than 120u/dl (Figure 2.3: linear 
regression R^=ll%, t=-3.58, p=0.001).
This procedure was repeated to determine if the relationship between FVc and 
APC:SR persisted when high values of factor VIIIc were excluded from the 
analysis. 57 subjects had factor VIIIc levels less than 120 iu/dl. In this group 
a significant correlation between factor Vc and APC:SR was observed (Figure 
2.4: linear regression R^=10.5%, t=-2.52, p= 0.01).
Free protein S levels also showed a significant correlation with APC:SR in the 
37 individuals with levels of both factor Vc and factor VIIIc less than 120u/dl 
(linear regression R^=12.7%, t=2.26, p=0.03).
2.3.4 Relationship between APC:SR, placental weight, fetal weight and Fl+2
No significant difference in placental weight was observed between those with 
acquired APCR and those with a normal APC:SR (acquired APCR mean 
placental weight 631g vs 614g, two sample t test p>0.05). In subjects with 
acquired APCR smaller birth weights were observed (mean weight 3240g vs 
3566g, difference 320g, two sample t test p=0.03).
For all FVL negative subjects, a significant inverse relationship between Fl+2 
levels and APC:SR (linear regression R^=16.7%, t=-4.08, p=0.001) was 
observed. In subjects sampled In the third trimester a similar relationship was 
observed (Figure 2.5, linear regression R^=21.4%, t=“3.30, p=0.001).
51
although a stronger positive relationship between Fl+2 and gestation (linear 
regression R^=30.7%, t=5.65, p=0.0001) was noted.
2.4 Discussion
2.4.1 This study provides data on APC response, protein C, protein S and other
haemostatic variables in 239 women during pregnancy. A 29% rise in factor 
Vc was observed from 6-11 weeks to 36-40 weeks gestation (mean, SD, 
p=0.01). In previous studies no consistent elevation of factor Vc has been 
reported[119, 120] although in the study by Stirling et at[119], an elevation 
of FVc was observed early in pregnancy and immediately after delivery. 
Higher levels of FVc have also been reported to occur in normal pregnant 
subjects at delivery[95]. Elevation of factor VIIIc was seen throughout 
pregnancy and is consistent with previous studies[119, 126]. It is likely that 
these changes are multifactorial, but relate in part to changes in hormones 
during gestation. These elevations persisted into the early puerperium. As 
with many previous studies no effect of gestation on AT activity was 
seen[125, 126]. Consistent with previous investigations PC activity showed 
no consistent trend with gestation[121, 122] and the protein C levels 
observed during pregnancy in this study are within the local reference range 
for protein C activity In equivalent age non-contraceptive using females[102]. 
A rise in PC activity at three days post-partum was observed. This is 
consistent with the rise in PC antigen levels in the immediate post-partum 
period previously reported[121]. The mechanism of the rise In PC levels in
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the puerperium is unclear, as PC is not considered to be an acute phase 
reactant[214]. Rising PC levels are seen in a number of clinical 
circumstances including oral anticoagulant withdrawal[215, 216], anabolic 
steroid usage[217] and in the late normalisation of reduced levels occurring 
after major surgery[218, 219]. In population-based studies a strong positive 
correlation between PC levels and lipids has been reported[220, 221]. An 
elevation in blood lipids has been reported to occur at the end of 
pregnancy[222] and, as no reduction in PC values Is seen in normal 
pregnancy this elevation of lipids may contribute to the rise in PC observed in 
the early puerperium.
2.4.2 The observed change in PSF level with increasing gestation is consistent with 
the recent study by Faught et al[223]. However, in the current study a 
progressive fall in PST with increasing gestation was observed. This was not 
observed by Faught et al, but has been previously reported[120, 123, 224]. 
The normal ranges for both PST and PSF at 6-11 weeks gestation are below 
the local normal ranges for non-oral contraceptive using females (PST: 64- 
154 iu/dl, PSF:54-154iu/dl) and suggest that a fall in protein S occurs during 
the first weeks of pregnancy. These changes present significant difficulty in 
the diagnosis of inherited protein S deficiency in pregnancy.
2.4.3 The mechanism of the physiological change in APC:SR has been attributed to 
elevation of factor VIIIc. Similar acquired APC resistance has been found in 
association with inflammatory disorders[83] and use of the combined oral 
contraceptive pill[94]. In this study, a fall in APC:SR was observed with 
increasing gestation in the absence of elevated anticardiolipin antibodies, a
53
prolonged APTT or the factor V Leiden mutation. This fall correlated with 
changes in factor VIIIc, factor Vc, and Protein S, but not with changes in 
haematocrit. This correlation between APC:SR and factor VIIIc persisted 
when subjects with factor Vc of > /= to 120u/dl were excluded from the 
analysis. The correlation between APC:SR and factor Vc also persisted when 
subjects with a factor VIIIc of >/=120iu/dl were excluded from the analysis. 
In the small number of subjects in the study with both factor Vc and factor 
VIIIc <120u/dl it was possible to find a correlation between PSF and APC:SR. 
These results show a relationship between factor VIIIc and APC:SR 
independent of factor Vc, but also suggest a potential role for factor Vc in 
APC resistance. Although APC:SR has been shown to be insensitive to Factor 
Vc levels at normal concentrations[212], the results suggest that high factor 
Vc levels may influence APC:SR and are In keeping with one other published 
study which has suggested that APC:SR may be affected by elevated factor 
Vc levels[213]. It has been suggested that protein S only influences APC:SR 
when protein S levels fall below 20% of normal[211]. It is possible in 
pregnancy that APC:SR may be affected by the extreme reduction in protein 
S values seen in some individuals in the latter stages of normal gestation.
2.4.4 The correlation of factor VIIIc with APC:SR is consistent with previous studies 
of APC:SR determinants[95, 124] and is in keeping with a previous 
longitudinal study of APC:SR in normal pregnancy[225], Although that study 
utilised different sample timing it reported similar changes in factor VIIIc and 
APC:SR between 28 and 37 weeks gestation as seen in this study. 
Modification of the APC:SR assay by pre-dilution of patient plasma with factor
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V depleted plasma abolished the pregnancy-associated change in APC:SR. 
This is presumably by normalisation of coagulation factors (except factor FVc) 
by dilution and is in keeping with the high specificity of the assay for the 
factor V Leiden mutation in a variety of clinical circumstances[81]. The 
normal range for mAPC:SR for the whole of gestation (2.0-2.76) is 
comparable with the local laboratory non-pregnant female reference range 
for mAPC:SR (2.2-2.6). The observed rise in Fl+2 between 12-17 weeks and 
24-28 weeks gestation is consistent with recent other studies utilising the 
same assay[134, 226] and indicates that a degree of activation of coagulation 
occurs at a relatively early stage in normal pregnancy.
2.4.5 A significant inverse relationship between the marker of thrombin generation 
Fl+2 and APC:SR was observed in this study. This may indicate that the 
APC:SR is related to thrombin generation. However further study is required 
to determine if this relationship Is independent of gestation. If acquired 
APCR results In an increase in thrombin generation, this may influence a 
number of outcomes of pregnancy which have been linked to thrombosis and 
heritable APCR, such as venous thrombosis and pre-eclampsia. Thrombin 
generation may also influence, and be influenced by, placental function and 
fetal development. In this study a small, but significant difference in birth 
weights was observed in comparison of those subjects with an APC:SR less 
than 2.6 and those with an APC:SR greater than 2.6 in the third trimester of 
pregnancy. This would be consistent with a relationship between the 
sensitivity to APC in pregnancy and fetal development.
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Figure 2.1 Changes In factors VIIIc, Vc, protein S 
and protein C with gestation
PST
PSF
17-23 wks 24-28 wks 29-35 wks
Weeks of Gestation
Legend Mean values for each variable against periods of pregnancy (weeks) and at 
3 days post-natal (3PN) are shown. Abbreviations for each factor are explained in 
Materials and Methods. FVc (diamond), FVIIIc (square), PST (triangle), PSF (open 
circle), PC (* ) .
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Figure 2.2 Changes in APC:SR and mAPC:SR with gestation
3.5 T
3 --
APCSR
2.5 "
mAPCSR
6-11 wks 12-16 Wks 17-23 wks 24-28 wks 29-35 wks
Weeks of Gestation
36-40 wks 3PN
Legend Mean values for each variable against periods of pregnancy (weeks) and at 
3 days post-natal (3PN) are shown. Abbreviations for each factor are explained in 
Materials and Methods. APC:SR (square), mAPC:SR (diamond).
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4.5
Figure 2.3 APC:SR vs FVHIc when FVc <120u/dl
wes
a .
<  3
2.5
A
A A A
15
40 80 120 160 200
F V I I Ic  ( i u / d l )
240 280 320 360
Legend Correlation of APC:SR and FVIIIc in subjects with a FVc level <120u/dl. 
For guidance a linear regression line is shown.
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Figure 2.4 APC:SR vs FVc when FVnic <120iu/dl
ce: 3.5Y)uo_
2.5
1.5
40 120 160
FVc (u /d l)
200 240
Legend Correlation of APC:SR and FVc in subjects with a FVIIIc level <120iu/dl. 
For guidance a linear regression line is shown.
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Fîgure 2.5 Prothrombin fragment 1+2 (F l+ 2 ) with APC:SR
3.5
3 -
2.5 -
1.5
Fl+2 (nmol/l)
Legend Correlation of APC:SR and prothrombin fragment 1+2 at 28-40 weeks gestation. 
For guidance a linear regression line is shown.
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Chapter 3
Acquired activated protein C resistance and markers of thrombin
generation
62
3.1 APCR associated with FVL has been shown to be associated with higher 
plasma levels of two markers of thrombin generation; Fl+2 and thrombin- 
antithrombin (TAT) complexes[227, 228]. TAT complexes are formed as 
thrombin binds to its principal inhibitor antithrombin. In view of this and the 
association between Fl+2 and APC:SR observed in Chapter 2, a further study 
of the relationship between thrombin generation and acquired APCR was 
carried out To exclude any influence of FVL, all individuals were screened to 
exclude this mutation. To exciude an effect of gestation, ail subjects were 
sampled at presentation for antenatal care and at 28-32 weeks gestation. 
Subjects with at least one successful pregnancy were chosen as these would 
constitute a homogenous low risk pregnancy group. Individuals with a 
history of fetal loss have been reported to have a higher prevalence of 
heritable thrombophilia[148] and subjects with a history of recurrent fetal 
loss have been shown to have higher levels of TAT (when assessed out with 
pregnancy)[229]. Consequently this study was designed to examine the 
relationship between APC:SR and the change in APC:SR with gestation with 
markers of thrombin generation and fetal weight. To refine the examination 
of fetal weight, birth weights were normalised for gestational age, sex and 
maternal parity.
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3.2 Materials and Methods
3.2.1 Subjects
A prospective longltudlnai study of 134 pregnant women (median age 30, 
range 25-35 years) was carried out. Consecutive parous subjects attending a 
routine antenatal clinic at Glasgow Royal Maternity Hospital were entered into 
the study. Subjects with at least one successful pregnancy were chosen as 
these would constitute a homogenous low risk pregnancy group. The study 
was approved by the hospital ethical committee and written consent was 
obtained from all participating subjects. To determine the significance of 
physiological changes in APC:SR, women with a personal history of VTE 
(n=l) or FVL (n=2) were excluded from the study. In a further 3 subjects, 
APC;SRs at presentation were not available.
3.2.2 Assay methodology
Blood sampling, plasma processing, APC:SR, Fl+2 and FVL analyses were 
carried out as detailed in Chapter 2. APC:SRs were assessed at presentation 
for antenatal care (median gestation 12 weeks, range 7-15) and at 28-32 
weeks gestation. Fl+2 and TAT concentrations were measured at 28-32 
weeks gestation. TAT concentrations were measured by ELISA (Enygnost; 
Behring, Marburg, Germany)[230]. Body mass index (BMI) for each subject 
was calculated at the time of the initial blood sample (kg/m^). All subjects
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had uncomplicated pregnancies. Case records were retrieved at six weeks 
after delivery and birth weight centiles were calculated by use of the Medical 
Research Council normogram[231].
3.2.3 Statistical analysis
As there is no published information on the significance of the change in 
APC:SR in pregnancy, simple subtraction was used to calculate the difference 
in booking and 28-32 weeks gestation APCtSRs and subjects were grouped 
into those with an increase (Group A, n=90, mean increase 0.43, SD 0.32) or 
no Increase (Group B, n=38) in resistance with Increasing gestation. 
Comparison of groups was carried out by Student t test analysis for 
parametric and Mann-Whitney U test for non-parametric data where 
appropriate. The relationships of APC:SR with age, height, weight, BMI, TAT, 
Fl+2 and birth weight centile were examined by linear regression using 
Minitab®for Windows® Release 11 statistical software (Minitab Inc, USA).
3.3 Results
3.3.1 No significant relationship between APC:SR and gestation between 7 and 15 
weeks was observed (mean APC:SR 2.76, SD=0.38.) At 7-15 weeks no 
relationship of APC:SR with blood group, smoking history (Table 3.1), age, 
height, weight or BMI (Table 3.2) was observed.
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3.3.2 A fall in APC:SR (mean fall 0.43, SD=0.32) was observed in 90 subjects. This
group (group A) was defined as showing an increase in APCR with gestation.
No difference in TAT or Fl+2 values was observed in comparison with those 
individuals in which no increase in APCR (n=38) was observed (group B). 
The median birthweight centile in the offspring of women of group A (median 
centile 49, I.Q.R. 18-75) was significantly lower (Mann-Whitney U test 
p=0.02) than those in group B (median centile 67, I.Q.R 41-82). These 
results are shown In Figure 3.1.
3.3.3 No relationship of APC:SR with gestation between 28 and 32 weeks was 
observed (mean APC:SR 2.50, SD=0.37). At 28-32 weeks gestation a
significant inverse relationship between APC:SR and TAT concentration
(mean 7.25pg/l, SD=2.6) was observed (Figure 3.2: linear regression 
R^=3.8%, t~-2.11, p=0.03). No significant relationship between smoking, 
blood group (Table 3.1), age, booking weight, height, booking BMI (Table 
3.2), Fl+2 (mean 2,95 nmol/l, SD=0.90) or birthweight centile and 28-32 
week APC:SR was noted.
3.4 Discussion
3.4.1 Unlike non-pregnant subjects[232] no relationship between APCiSR and BMI 
at booking was observed. No relationship between cigarette smoking and
APCiSR was found in this study. This may be due to the sample size of the 
study as the larger study detailed in Chapter 4 detected a significant positive 
relationship between APC:SR and smoking.
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3.4.2 Normal gestation is associated with a progressive increase in thrombin 
generation[233]. Additionally, Increased markers of thrombin generation, in 
non-pregnant women, have been associated with a history of recurrent 
miscarriage[229]. An increase In thrombin generation has also been reported 
in APCR associated with FVL[228]. In this study a significant inverse 
relationship between the APC:SR at 28-32 weeks gestation and TAT complex 
levels in plasma was observed. This relationship appeared to be independent 
of gestation and suggests that the level of APCR in plasma during pregnancy 
may reflect thrombin generation. This would be consistent with the 
association of elevated FVIIIc[85] and protein S deficiency[208] with venous 
thrombosis.
3.4.3 Although an inverse relationship between APC:SR and Fl+2 was observed in 
Chapter 2 this association was not confirmed in this study. This apparent 
disparity cannot be explained by the different case-mix of the two studies 
and comparable F I+2 levels were observed in both. That the relationship 
between Fl+2 and APC:SR was not confirmed when the confounder of 
gestation was removed suggests that the influence of gestation on both 
APC:SR and Fl+2 resulted in the correlation of APC:SR and Fl+2 observed in 
Chapter 2. It is conceivable that TAT complex levels more sensitively 
represent thrombin generation as Fl+2 has been reported to be less 
sensitive than TAT to changes in thrombin generation during warfarin 
therapy[234]. Flowever both assays do appear to have similar profiles in 
subjects with FVL[227].
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3.4.4 In 70.3% of pregnant subjects an increase in APCR with gestation was 
observed in the absence of the FVL mutation. The significance of this 
physiological adaptation has not previously been studied. In subjects 
demonstrating an increase in ACPR with gestation, no significant difference in 
markers of thrombin generation was observed in comparison to subjects in 
whom no Increase in APCR was noted. However significantly smaller birth 
weight centiles were observed in those demonstrating an increase in ACPR. 
The mechanism of this association is unknown. However as with the study 
described in Chapter 4, it is of interest that those subjects who do not show 
an increase in APCR with gestation have lower APC:SR values at 7-15 weeks 
gestation (mean 2.50 vs 2.84, t=4.99, p=0.00001).
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Table 3.1 APC:SR at 7-15 weeks and 28-32 weeks gestation 
compared with blood group and smoking
APC:SR 
7-15 weeks TTestP
APC;SR 
28-32 weeks TTestPmean SD mean SD
Blood group 
0 2.78 0.37
>0.05
2.56 0.43
>0.05
Non-group 0 2.70 0.42 2 ^ 2 0.32
Smoker 2.76 0.38
>0.05
2.50 0.40
>0.05
Non-smoker 2.73 0.41 2.47 0,36
Legend APC:SR values (mean and SD) for blood group 0 , non-blood group O, smokers 
and non-smokers are shown at 7-15 and 28-32 weeks gestation. The p values of the t 
test comparisons of APC:SR for blood group 0  vs non-blood group 0  and for smokers vs 
non-smokers at both 7-15 and 28-32 weeks gestation are shown.
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Table 3.2 The relationship of APC:SR with age, height, weight
and BMl
At
7-15
weeks
APC:SR
7-15
weeks
APC:SR
28-32
weeks
mean SD RZ T P r 2 T PAge
(yrs) 30 3 0.0% 0.24 0.8 0.5% -0.78 0.4
Height
(m) 1.63 0.06 0.0% 0.03 0.9 0.5% 0.79 0.4
Weight
(kg) 68.5 14.2 0.0% -0.1 0.9 0.6% 0.91 0.4BMI
(kg/m ')_ .. 25.7 5.0 0.0% -0.16 0.9 0.3% 0.61 0.5
Legend The mean and SD of age, weight, height and body mass index (BMI) at 7-15 weeks 
gestation is shown. The results of linear regression analysis of each parameter with APC:SR 
at 7-15 and 28-32 weeks gestation Is shown.
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Figure 3.1 Comparison of birthweight centile in Group A vs Group B
100 
90 
80 
70 
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50 —  
40 
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0  1—
G roup A
 [-------
Group B
Legend Median (line), upper and lower limits of interquartile range (upper and 
lower box limits) are shown for those subjects with an increase (Group A) or no 
increase (Group B) in APCR with gestation.
Figure 3.2 TAT concentration vs APCiSR at 28-32 weeks gestation
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Legend The relationship between APC:SR and TAT (ug/i) at 28-32 weeks 
gestation is shown. A linear regression line is shown.
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Chapter 4
The relationship between APCR, pregnancy outcome, the full blood 
count and bleeding in pregnancy
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4.1.1 In keeping with its prothrombotic potential, a number of studies have 
suggested that heterozygous carriage of FVL confers at least a 2 fold risk of 
both pregnancy-induced hypertension[152, 184, 185] and late fetal loss[148, 
201]. However, as it seems likely that the FVL mutation was present in the 
first Europeans around 30-40,000 years ago (reviewed in[204]) and In view 
of its relatively high prevalence in European subjects[75], it has been 
speculated that FVL may confer a beneficial effect on the carrier. The most 
obvious potential advantage of an increase in thrombotic potential would be 
the reduction of blood loss and the protection of red cell levels. This 
hypothesis has been examined In pregnancy in a single study[205], which 
showed a significantly reduced risk of intrapartum bleeding and better 
preservation of the post-partum haemoglobin levels in FVL heterozygote 
subjects when compared to the non FVL pregnant subjects.
4.1.2 Changes in APCR, occurring in the absence of FVL, are seen in the majority 
of normal pregnancies (see Chapters 2 and 3). The influence of this 
physiological adaptation on the outcome of pregnancy is unknown. In family 
and case-controi studies, individuals with thrombosis (without FVL) have 
lower APC:SR values than non-thrombotic individuals[235, 236]. Low 
APC:SRs have also been associated with thrombosis in Japanese subjects 
who are unlikely to have FVL[237]. More recently de Visser et al have shown 
a 2.5 relative risk (C.I.95 1 .5-4.2) of venous thrombosis associated with the 
lowest quartlle of APC:SR in FVL negative subjects[238]. Whether the 
APC:SR (in the absence of FVL) influences the occurrence of thrombosis-
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linked complications of pregnancy such as fetal loss and pre-eclampsia is 
unknown.
4.1.3 To examine the significance of physiological changes In APCR during 
pregnancy, the APC:SR was examined, in a prospective longitudinal study of 
1046 subjects, at two time points during pregnancy. The APC:SR was 
analysed in relation to the demographics, personal and family history of the 
study population, as well as pregnancy outcome measures of maternal blood 
loss, changes in maternal blood count and the occurrence of fetal loss and 
maternal hypertension.
4.2 Materials and methods
4.2.1 Subjects
1046 subjects (median age 29 years, interquartile range 25-32) who 
consecutively attended for routine antenatal care at the Glasgow Royal 
Maternity Hospital were recruited. Ethical approval was obtained from the 
local ethical committee at the Glasgow Royal Infirmary NHS Trust and written 
consent was obtained from all participating subjects. The study was blinded 
to the subjects and their clinicians until 6  weeks after delivery of the current 
pregnancy. Past obstetric and medical history was collected by questionnaire 
at entry to the study and the data on the outcome of the current pregnancy 
was obtained by examination of case records six weeks after delivery.
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4.2.2 Laboratory Analysis
Blood samples were collected from the antecubltal vein at 7-15 weeks 
gestation and between 27 and 40 weeks gestation in all subjects. Plasma 
samples were anticoagulated in 1/10 volume of 0.105 M sodium citrate. 
Sample processing, APC:SR, mAPC:SR and mutation analysis for the G->A 
1691 mutation in the gene coding for coagulation factor V were assessed as 
detailed in Chapter 2. Samples for full blood count analysis were 
anticoagulated in K3 EDTA. Analysis of full blood count parameters (white 
blood cell count (WBC), red cell count (RBC), haemoglobin (Hb), haematocrit 
(HOT), mean red cell volume (MCV), mean cell Hb concentration (MCHC), red 
cell distribution width (ROW) and platelet count) was carried out using the 
Coulter 'GenS' System (Coulter Electronics, USA).
4.2.3 FVL classification
The APC:SR and the modified APC:SR were measured in all subjects between 
7-15 weeks gestation. The mAPC:SR has been shown to be highly specific 
for the FVL mutation in a variety of circumstances[209, 239] and is 
unaffected by gestation (Chapter 2). Svensson et al [239] have shown that 
in normal, non pregnant subjects (and in those presenting with VTE) the 
mAPC:SR is 98.8% specific and 100% sensitive for FVL at greater than/equal 
to 1.7 SD below the mean mAPCiSR for normal control subjects. To ensure 
exclusion of FVL in this study a more stringent cut off of >1.3 SD below the
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mean was employed. Subjects with an mAPC:SR >1.3 SD below the mean 
(n=100) underwent direct mutation analysis for the G-+A 1691 mutation. 37 
Subjects were found to be heterozygous for the FVL mutation. All FVL 
positive subjects lay beyond 2 SD below the mean (Figure 4.1 mAPC:SR 
range 1.37-1.72). 1009 subjects were classified as FVL negative (mAPC:SR 
1.49-4.0). In 583 non-FVL subjects the APC:SR was also measured at 27-34 
weeks gestation. In the remainder the second APC:SR assessment was 
carried out beyond or before this gestation and to exclude an effect of 
gestation on the APC:SR these subjects were not Included in the analysis.
4.2.4 Definition of pregnancy-induced hypertension (PIFI) and pre-eclampsia (PET)
PIH was defined as diastolic BP >90 mmHg on two or more occasions 4 
hours apart, in subjects normotensive at recruitment, with no history of 
hypertension. PET was defined as PIH with >2+ proteinuria.
4.2.5 Statistical Analysis
Relationships between FBC parameters and APCiSR were assessed by linear 
regression analysis. Comparison of blood count parameters between FVL 
positive and negative subjects was carried out using the two sample Y  test. 
Comparison of non-parametric data was achieved by Mann-Whitney U test 
(MW) analysis. Comparison of continuous variables was achieved by linear 
regression. These analyses were completed on Minitab®for Windows®
76
Release 11 statistical software (Minitab Inc, USA). Comparison of categorical 
data was achieved by Mantel and Haentzel Odds Ratio analysis (ORmh)-
43  Results
4.3.1 APC:SR and mAPC:SR values
The mean value of APC:SR at 7-15 weeks for all subjects was 2.72 (SD 0.56). 
The mean value for mAPC:SR for all subjects at 7-15 weeks was 2.28 (SD 
0.25). In the FVL negative group no correlation with gestation and APC:SR 
was observed between 7 and 15 weeks. Similarly there was no correlation of 
APC:SR with gestation between 27 and 34 weeks. In the current pregnancy, 
83 (of 1046) subjects developed PIH and 22 PET. PIH occurred in 11.9% 
and PET in 2.5% of primigravid women.
4.3.2 Comparison of FVL negative with FVL positive subjects
The results are summarised in Table 4.1. In first degree relatives of the 
whole study group a family history of venous thromboembolism (VTE) was 
noted in 11.7%, and of PIH in 10.6%. There was no significant difference in 
the occurrence of a positive family history of VTE, PIH, cerebrovascular 
disease (CVD), or ischaemic heart disease (IHD) in the FVL positive subjects 
when compared with the FVL negative subjects. No significant difference in 
the occurrence of PIH in previous pregnancies or of personal history of VTE
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was observed between the two groups. In the index pregnancy no 
significant difference in the occurrence of hypertensive disorders was 
observed between FVL positive and negative subjects.
Blood count and Blood Loss
No significant difference in any FBC parameter at either 7-15 weeks or 27-34 
weeks was observed between FVL positive and negative subjects (Table 4.2). 
Furthermore, no difference in the change of FBC parameters during 
pregnancy between the groups was observed. In the comparison of FVL 
positive and negative subjects (Table 4.3) there was no significant difference 
in the occurrence of excess blood loss at delivery (estimated by eye at 
>500mls) or blood loss at delivery requiring additional syntometrine therapy, 
transfusion or surgery. No difference was found when analysis was restricted 
to those subjects who had had a spontaneous vertex delivery (SVD) which 
did not require instrumentation. No significant difference in the occurrence 
of post-partum haemorrhage (PPH) or PPH requiring readmission, 
syntometrine or surgery was observed between the two groups. A similar 
result was obtained when the analysis was restricted to SVD subjects. 
Anaemia of less than lOg/dl at any gestation was observed in 187 of 1046 
subjects. No significant difference in the occurrence of anaemia was 
observed when FVL positive and negative subjects were compared. Per- 
vaginal blood loss was reported in 145 subjects prior to 24 weeks gestation 
and in 102 subjects at or after 24 weeks gestation (72 subjects required
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admission, although none required blood transfusion). No difference in the 
occurrence of blood loss was observed in comparison of FVL positive and 
negative subjects.
Pregnancy Outcome
11 subjects (of 1046) had a miscarriage between booking for antenatal care 
and 24 weeks gestation. 12 subjects suffered fetal loss at or after 24 weeks 
gestation. No miscarriages or fetal losses were noted in FVL positive 
subjects. There were 3 neonatal deaths. Two occurred in the FVL positive 
group (ORmh 57.6, C.I.95 5.1-647). One of these was found to have suffered 
neonatal asphyxia and the other to have multiple developmental anomalies.
4.3.3 The APC:SR in FVL negative subjects
No significant difference in APC;SR at 7-15 weeks was observed when those 
subjects with and without a family history of VT, IHD, PIH, or CVD in a first 
degree relative were compared. In those subjects with a history of PIH in a 
previous pregnancy there was no difference in the APCiSR at 7-15 weeks or 
27-34 weeks. No relationship between the APC:SR at 7-15 weeks and waist 
circumference, weight, body mass index, age, alcohol consumption or 
diastolic blood pressure at recruitment was observed (Table 4.4). Lower 
APC:SRs were noted in non-blood group 0 individuals at both 7-15 weeks 
(mean 2.67, SD 0.45 vs 2.81, SD 0.42: t=4.61, p<0.00001) (Figure 4.2) and
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27-34 weeks gestation (mean 2.36, SD 0.31 vs 2.49, SD 0.38: t=4.68, 
p<0.00001). Lower APC:SRs were also observed In non-smokers (Figure 4.2) 
at both 7-15 weeks (mean 2.72, S.D. 0.45 vs 2.79, S.D. 0.43: t--2.29, 
p<0.02) and 27-34 weeks (mean 2.40, S.D. 0.34 vs 2.49, S.D. 0.36: t=-3.12,
p<0.0002).
Blood count and Blood Loss
No significant relationship between WBC, RBC or platelet count at 7-15 weeks 
and the APC:SR at 7-15 weeks was observed, although a positive relationship 
between the APC:SR at 7-15 weeks and the 27-34 week Hb (linear regression 
R^=0.7%, p=0.02), HCT (R^=0.6%, p=0.04), MCV (R^=1.2%, p=0.004) and 
MCH (R^=1.2%, p=0.003) was noted. At 27-34 weeks a similar slight, but 
significant, positive relationship between the RBC (R^=0.7%, p=0.04), Hb 
(R^=2.7%, p=0.0001), MCH (R^=1.0%, p=0.02) and the APC;SR at 27-34 
weeks was observed. However a much greater negative relationship of 
gestation with APC:SR (R^=13.3%, p=0.0001), Hb (R^=39.3%, p=0.0001) 
and RBC (R^=37.3%, p=0.0001) was observed. No significant difference In 
APC:SR was observed in comparison of subjects who experienced per-vaginal 
blood loss during pregnancy or subjects who experienced excess loss of 
blood during delivery or in the early puerperium.
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Pregnancy Outcome
A significantly lower APC:SR at 7-15 weeks was observed In subjects, 
normotensive at recruitment and with no past history of hypertension, who 
subsequently developed PIH in the current pregnancy (mean APC:SR 2.64, 
SD 0.34 vs 2.76, SD 0.45, t=-2.89, p=0.004. Figure 4.3). A more marked 
difference was observed in subjects who developed PET (mean APCiSR 2.50, 
SD 0.26 vs 2.75, SD 0.44, t=-4.26, p=0.0003, Figure 4.3). A significant 
difference for PIH persisted when the analysis was restricted to primigravid 
subjects (mean APC:SR 2.64, SD 0.31 vs 2.76, SD 0.41, t=-2.23, p=0.03) 
and although a lower mean APC:SR was noted in primigravid subjects who 
subsequently developed PET (mean APC:SR 2.52, SD 0.316 vs 2.76, SD 
0.41), this did not reach statistical significance (p=0.08). There was no 
relationship between the APC:SR and the occurrence of PIH or PET when the 
APCiSR was measured at 27-34 weeks gestation.
4.3.4 Changes in APC:SR with gestation
Of 594 subjects, in whom an APC:SR was available at both 7-15 and 27-34 
weeks, 467 subjects showed an increase in APCR with increasing gestation 
(mean increase 0.50, SD 0.39). In the remainder no increase in resistance 
was observed. FBC parameters for each group are shown in Table 4.5. No 
significant difference in any FBC parameter at 7-15 weeks or 27-34 weeks 
gestation was observed. The changes in the red cell parameters between 7-
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15 and 27-34 weeks gestation for those subjects with an increase in APCR 
with gestation are shown in Figure 4.4.
A significantly increased relative risk of PIH (ORmh=2.0, C.I.95 1.1-3.6) and 
PET (0R m h=3.1 , C.I.95 1.2-8.0) in the current pregnancy was observed in 
those subjects In whom no increase In APCR was seen In comparison with the 
group in which APCR increased from 7-15 to 27-34 weeks. This unexpected 
relationship may be explained by the observation that significantly lower 
APC:SRs at 7-15 weeks (mean APCiSR 2.41, SD 0.27 vs 2.84, SD 0.45, t=- 
13.18, p=0.00001) and at 27-34 weeks (mean APC:SR 2.74, SD 0.49 vs 2.50, 
SD 0.26, t=8.54, p=0.00001) were observed in subjects in whom no increase 
in resistance with gestation was observed.
In those subjects who suffered fetal loss or neonatal death there was no 
difference in the APC:SR at either 7-15 weeks or 27-34 weeks when 
compared with those with a live birth.
4.4 Discussion
4.4.1 As shown in Chapter 2, acquired APCR in pregnancy relates, in part, to FVIIIc 
levels. An association between blood group and FVIIIc levels has previously 
been documented[87], with higher FVIIIc levels noted in non-blood group O 
subjects. The, finding of higher APC:SR values in blood group 0 individuals 
when compared with non-blood group 0 is consistent with an influence of 
blood group on APCR in studies of non-pregnant subjects[232]. In contrast 
to a previous study[240], no relationship between blood group and PIH or
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PET was observed. Body mass index (BMI) in early pregnancy Is known to 
be important in the subsequent development of PET. Although this was 
confirmed in this study, no relationship between booking BMI and APC:SR at 
any gestation was observed. Waist circumference has been suggested as an 
independent predictor of the development of ischaemic heart disease in the 
general population[241]. In this study a significant relationship between 
waist circumference and the development of PIH (median 81.0 cm vs 77.5 
cm, p=0.00001) and PET (median 80.5 cm vs 78.0 cm, p=0.02) was 
observed. However no relationship between waist circumference and APC:SR 
was noted.
4.4.2 The finding of higher APC:SRs in smokers is compatible with the reduced risk 
of PIH[240] and reduced thrombin generation[226] associated with smoking 
in pregnancy. The association of lower APCiSR levels early in pregnancy and 
subsequent PIH suggests that the control of APCR may be important in the 
development of this condition. As APCR, due to FVL, has been implicated in 
the development of PET, this study parallels the recently observed 
association between APCR (occurring in the absence of the FVL mutation) 
and venous thrombosis[238]. Both these observations would be consistent 
with the evidence of thrombosis in pre eclamptic placentas[155]. That the 
balance of coagulation early in pregnancy reflects the occurrence of clinical 
PET later in pregnancy is consistent with the observation that the failure of 
normal placental development which characterises PET is found early in 
pregnancies which subsequently develop the condition[153]. That there is no 
relationship between acquired APCR, measured at 27-34 weeks, and PIH may
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be due, in part, to the occurrence of clinically evident PIH or PET prior to 35 
weeks gestation. 31% of PIH cases and 41% of PET cases occurred prior to 
this time. A lack of sensitivity of the APC:SR at this gestation may relate to 
the consumption of FVIIIc which has been reported to occur during clinically 
evident PET[242]. A reduction of available FVIIIc in subjects during PET 
would result in a rise in APC:SR.
4.4.3 A small, but significant, relationship between APC:SR and FBC parameters 
was observed. However, no difference in the FBC at 7-15 or 27-34 weeks 
gestation was noted when subjects showing an increase In APCR were 
compared to those with no increase. In addition, a much stronger 
relationship between gestation itself and FBC was observed. This suggests 
that changes in APCR are not the main influence on the blood count in 
pregnancy.
4.4.4 The observation of a significant association between the carriage of FVL and 
neonatal death is unlikely to be of biological significance given the small 
number of cases observed and the presence of significant alternative 
aetiologies of neonatal death in each case.
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Figure 4.1 The mAPC:SR and Factor V Leiden
200
I  100
1.3 SD below mean
2 SD below mean
I T------- I"— I------1— —I----- 1------1------ i------r— T
1.3 1.4 1.5 1.6 17 1.8 1.9 20 2.1 22 23
mAPC :SR at 7-15 weeks
Legend A histogram of the mAPC:SR at 7-15 weeks gestation Is shown. 
Subjects positive for FVL are shown In blue. Subjects negative for FVL 
are shown In yellow. The arrows indicate 1.3 SD and 2 SD below the 
mean value of mAPC:SR for all subjects at 7-15 weeks gestation.
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Figure 4.2 APC:SR at 7-15 weeks with smoking 
and blood group
A P C .  S R
3 .5
3 .0
2.0
C i G S GROUP O
Legend Mean and interquartile ranges for APC:SR are shown for smokers (CIGS + )  
vs non-smokers (CIGS -) and blood group 0  + (GOUP 0  + ) vs non blood group O 
subjects (GROUP 0 -).
Figure 4.3 APC:SR at 7-15 weeks and occurrence of PIH or 
PET in the current pregnancy
3 .5
3 .0
APC:SR
2 .5
2.0
PET PIH
Legend Mean and interquartile ranges are shown for APCiSR for subjects with 
pre-eciampsia (PET + ) vs no PET (PET -) and pregnancy-induced hypertension 
(PIH + ) vs no PIH (PIH -).
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Chapter 5
Thrombin Induction of intercellular adhesion molecule-1 (ICAM-1) 
expression on human monocytes
93
5.1.1 From the studies detailed in Chapters 3 and 4, acquired APCR is associated 
with an increase in thrombin generation and appears linked to the occurrence 
of pre-eclampsia (a condition which Is associated with both heritable 
thrombophilic disorders, infiltration of the placenta by 
monocyte/macrophages and an increase in the inflammatory response -  
Chapter 1). In Chapter 5 and 6 the link between acquired APCR and 
inflammation was investigated. This investigation centred on the expression 
of adhesion molecule ICAM-1 (CD 54) on the human monocyte. An increase 
In ICAM-1 expression is likely to increase the recruitment of leukocytes to the 
Inflammatory response. As detailed in Chapter 1, thrombin can increase the 
expression of ICAM-1 on the endothelium. It is not known whether thrombin 
can also modulate the expression of ICAM-1 on the monocyte. Such an 
interaction would link thrombin to the pro-inflammatory response of the 
monocyte,
5.1.2 In this chapter the influence of thrombin on monocyte ICAM-1 expression in 
vitro was investigated. The effect of human alpha thrombin on monocytes 
from normal human donors was examined to determine if a specific dose- 
response relationship between monocyte ICAM-1 and thrombin could be 
observed. The response of monocyte ICAM-1 to thrombin was also examined 
on the monocyte cell line THP-1. To prove the specificity of the response the 
effect of the thrombin receptor agonist peptide (TRAP-6) and a pre-incubated 
mixture of thrombin with the direct thrombin inhibitor hirudin on ICAM-1 
expression was also investigated.
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5.1.3 ICAM-1 expression was measured by means of flow cytometry to allow the 
quantifiable assessment of a dose-response. Flow cytometric measurement 
would also allow examination of expression with minimal sample 
manipulation and facilitate more direct comparison with the investigation of 
in vivo monocyte ICAM-1 expression and soluble ICAM-1 levels detailed in 
Chapter 6.
5.2 Materials and Methods
5.2.1 Subjects
Monocytes were obtained from whole blood from 8 healthy volunteers (7 
female, 1 male, age range 25-40 years). The response of these cells to 
incubation, human alpha thrombin (Alpha Laboratories, UK), the thrombin 
receptor agonist peptide SFLLRN (TRAP-6, Bachem, UK) and a pre-incubated 
mixture of thrombin and a direct thrombin inhibitor hirudin (Alpha 
Laboratories, UK) was examined.
5.2.2 Human monocyte ceil line THP-1 cells
The human monocyte cell line THP-1, a cell line derived from acute 
monocytic leukaemia cells (European Collection of Animai Cell Cultures, 
Salisbury, UK), was cultured in liquid phase to allow flow cytometric analysis 
of ICAM-1 expression. Cells were cultured in standard culture media: RPMI-
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1640 (Sigma, UK) supplemented with 10% fetal calf serum (PCS, ICAN Flow, 
UK), 2mmol/l L-glutamine, 100 iu/ml penicillin and 100 pg/ml streptomycin 
(Gibco BRL, UK). The concentration of cells in the final reaction mixture was 
^500,000/300pl. Cells were Incubated with human alpha thrombin TRAP-6 
and thrombin, pre-incubated with hirudin. THP-1 cell viability, after 24 hour 
incubation was >90% determined by trypan blue exclusion.
5.2.3 Human peripheral blood monocyte preparation
Human peripheral blood monocytes were prepared from whole blood 
anticoagulated in 1/10 volume of 0.105 M sodium citrate by density gradient 
centrifugation. For each experiment 40 ml of blood was centrifuged against 
Lymphoprep (Nycomed, UK) at 300g for 15 minutes. The resultant cells were 
resuspended in RPMI 1640 (Sigma, UK) supplemented with 10% fetal calf 
serum (FCS, ICAN Flow, UK), 2mmol/l glutamine, lOOiu/ml penicillin and 
100p.g/ml streptomycin (Gibco BRL, UK). The final concentration of 
monocytes was 2.16 x 10^ /1. Cell viability for each procedure, after the 24 
hour incubation, was >95%, as determined by trypan blue exclusion.
5.2.4 Thrombin, TRAP-6 and thrombin-hirudin stimulation of monocytes
Human alpha thrombin (Alpha Laboratories, UK), diluted in 0.5% bovine 
serum albumin, CBSA', Sigma, UK) was added to human monocyte and THP- 
1 cell suspensions in a final reaction volume of 300pl. Thrombin at 0.75 iu,
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3.1 iu, 6.25 iu, 12.5 iu, 18.75 iu and 25 lu/300|il reaction mix was added to 
cell suspensions for 24 hours at 37°C in a 5% €02/95% air humidified 
atmosphere. Cells were also stimulated with TRAP-6 for 24 hours at a final 
concentration of 2pg/ml, 5 ^g/ml and lOpg/ml. Cell suspensions were also 
incubated with a mixture of 1.5 iu of thrombin, pre-incubated for one hour at 
37°C with 15 antithrombin units of hirudin (Alpha Laboratories, UK).
5.2.5 Flow cytometric analysis of thrombin/TRAP and thrombin-hirudin stimulation 
of ICAM-1 expression
Flow Cytometry principles
The Facscan Flow Cytometer (Becton Dickinson Ltd, UK) analyses the optical 
properties of single cells moving in a fluid stream through a focused argon 
laser beam. The forward scatter of incident light on the cell indicates the 
relative size of the cell and the side scatter indicates relative granularity. The 
flow cytometer can also measure the fluorescence emitted by various dyes or 
fluorescent-labelled antibodies. The fluorochromes absorb energy from the 
laser and release the absorbed energy by vibration, heat and by emission of 
photons of a longer wavelength. The fluorochrome Fluorescein 
Isothiocyanate (FFFC) emits at ~515nm and is detected on channel FL-1 and 
Phycoerythrin (PE) emits at ~580nm and is detected on channel FL-2 of the 
flow cytometer. The amount of fluorescent antibody a cell will bind (the
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fluorescence intensity) is proportional to the number of antibody binding sites 
on the cell.
Sample Preparation
Monocytes were identified by antiCD14. CD14, a receptor which binds the 
complex lipopolysaccharide-binding proteins, is expressed on 90-95% of 
monocytes[243] and is considered to be a specific monocyte marker for use 
in identification of monocytes in flow cytometric analysis. Monoclonal 
antibodies against CD54 (ICAM-1[244]) were used to quantify ICAM-1 on the 
monocyte surface. Mononuclear cell preparations and THP-1 cells were 
stained using anti-CD14 PE (Becton Dickinson Ltd, UK) and anti-CD54 FITC 
(Dako Ltd, UK) allowing simultaneous identification of monocytes and 
quantification of antibody binding to CD54. Cell counts per tube were 
adjusted to 1 x 10® cells in phosphate-buffered saline (PBS) azide containing 
2% blood group AB serum (PBS-AB) to a final volume of lOOpl. The 
appropriate volumes of anti-CD14 and anti-CD54 were added and incubated 
at room temperature for 15 minutes. 2 ml of FACS lysing solution (Becton 
Dickinson Ltd, UK) was added and incubated for 10 minutes at room 
temperature prior to centrifugation. After the supernatant was discarded, the 
resultant preparation was washed once in PBS-AB. The cells were then re­
suspended in 0.5ml PBS-azide. Isotype and fluorochrome matched mouse 
immunoglobulin was used as a negative control.
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Analysis and quantification
Samples were acquired on a Facscan Flow Cytometer (Becton Dickinson Ltd, 
UK) using Lysis II software with a logarithmic amplification of the FLl and 
FL2 signals. List mode data were collected from a minimum of 5000 events 
for each tube by 'live gating' on the CD14 positive monocyte population. The 
monocytes were then analysed to determine the mean fluorescence intensity 
(MFI) of CD54 on the monocyte population (a sample output showing the 
MFI is shown in Figure 5.1). The CD54 MFI was then converted into antibody 
binding capacity (ABC), using the Quantum Simply Cellular Microbeads Kit 
(Sigma Ltd, UK). The ABC is a measure of the number of antibodies bound 
per cell[245, 246]. This kit contains a set of standards to calibrate the MFI 
into equivalent units of Antibody Binding Capacity (ABC) for CD54. This 
standardisation facilitates the assessment of a dose-response relationship 
between a stimulus and the MFI of antibody binding as well as inter­
laboratory comparison of results.
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5.3 Results
5.3.1 In vitro monocyte stimulation with thrombin and TRAP-6: preliminary
experiments to determine optimal incubation and dose
ICAM-1 expression was measured after 0, 4, 24 and 48 hrs Incubation at 37°
C with 0, 6.25 and 25 IU/300pl of human aipha thrombin. The rise in ICAM-1 
expression in the absence of thrombin with time is shown as MFI (Figure 5.2) 
and ABC (Figure 5.3). Results of incubation with 6.25 and 25 IU/300pl alpha 
thrombin are also shown in Figure 5.3. At 48 hours, a fall in total ICAM-1 
expression in control and thrombin treated cells at all concentrations, when 
compared with 24 hour values, was observed. This pattern is consistent with 
a previous study of isolated monocyte ICAM-1 response to incubation[247] 
and is consistent with the maximal up-regulation of monocyte ICAM-1 at 24 
hours noted prevlously[248]. All subsequent experiments were conducted at 
24 hours.
5.3.2 The dose response of human monocyte ICAM-1 to thrombin and TRAP-6
A dose-response relationship between thrombin and human monocyte ICAM- 
1 expression at 24 hours was observed (Figure 5.4). At 24 hours incubation 
with 25IU thrombin, a mean rise in ICAM-1 expression of 54278 ABC (184%) 
over 24 hour control values was observed (Table 5.1). This rise is equivalent 
to the rise In mean fluorescence intensity of CD54 observed on monocytes
1 0 0
exposed to glutamine[249]. A rise of 143-147% (mean 25,080 ABC) in 
ICAM-1 expression was observed at 24 hours on incubation with 2pg/ml to 
lOug/ml of TRAP-6. In a separate experiment, incubation of human 
monocytes with 1.5 IU/300pl of thrombin resulted in an increase (over 
control) of 46,709 ABC at 24 hours. Repeating the experiment with pre­
incubation of thrombin with 30IU of the thrombin inhibitor hirudin resulted in 
inhibition of the ICAM-1 response (maximal rise </= 3,633 ABC).
5.3.3 The dose response of THP-1 ICAM-1 to thrombin and TRAP-6
Incubation of THP-1 cells at 37°C for 24 hours resulted in little increase in 
baseline ICAM-1 ABC (mean rise 560). Incubation with 25 IU/300pl of 
thrombin for 24 hours resulted in a mean rise of 24,222 ABC over 24 hour 
controls (Table 5.1). As with human cells, pre-incubation of thrombin with 
hirudin resulted in a failure of elevation of ICAM-1 expression. In a separate 
experiment incubation of THP-1 cells with TRAP-6 (at 5|ag/ml) for 24 hours 
resulted in an increase of 22,084 ABC compared with 24 hour control values 
(Table 5.1).
5.4 Discussion
5.4.1 In addition to a central role in coagulation, thrombin has been shown to have 
an important role in the co-ordination of the inflammatory response. 
Thrombin can induce selectin[9, 10] and adhesion molecule expression[ll]
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on the endothelial surface and thereby induce leukocyte adhesion and 
subsequent activation. Thrombin, in-vitro, has also been shown to be 
capable of influencing the inflammatory and coagulation repertoire of the 
monocyte by stimulation of interleukin-1, TNFa[64] and plasminogen 
activator inhibitor-2[65] expression. Monocytes also function as antigen 
presenting cells in the immune system, a function which is influenced by the 
expression of the LFA-1 ligand ICAM-1 (CD54) on the cell surface. Thrombin 
is aiso capable of activating T ce!ls[12], which express LFA-1, the ligand for 
ICAM-1.
5.4.2 The present findings show that thrombin also has a direct effect on monocyte 
ICAM-1 expression. Thus activation of the coagulation system may directly 
influence the monocyte inflammatory response. This may be important in 
vascular injury and disorders such as atherosclerosis and pre-eclampsia, 
where vascular damage is characterised by deposition of lipid-laden 
macrophages[154, 155]. A similar, in-vitro, induction of monocyte ICAM-1 
with the hexapeptide SFLLRN (TRAP 6) was observed. SFLLRN has been 
shown to be a specific thrombin receptor activator[250, 251], suggesting that 
thrombin induction of monocyte ICAM-1 is due to an interaction of thrombin 
with its specific receptor[6]. Furthermore the thrombin action appears 
specific as it was inhibited by hirudin, a specific thrombin inhibitor and was 
also demonstrated on the monocyte cell line THP-1.
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Table 5.1 The response of human monocytes and THP-1 cells to 
human alpha thrombin and SFLLRN (TRAP-6)
Human
MeanICAM-1 
rise over 24hr 
control (ABC)
Mean ICAM-1 
rise over 24hr 
control (% )
THP-1
Mean ICAM-1 
rise over 24hr 
control (ABC)
Mean ICAM-1 
rise over 24hr 
control (% )
24 hr + 
Thrombin
(25IU/300U1)
54278 184% 24,222 235%
24 hr + 
TRAP
(5ug/ml)
24,827 145% 22,084 222%
Legend The mean rise (and percentage rise) in monocyte ICAM-1 in response 
to the maximal dose of thrombin (25iu/300ui) and TRAP-6 (TRAP 5ug/ml) at 24 
hours incubation in human m onocles and THP-1 cells is shown.
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Figure 5.1 ICAM-1 (CD54) expression on human monocytes
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Legend ICAM-1 expression (CD54) on isolated monocytes at 0 hours Incubation in the 
absence of thrombin.A mean fluorescence of 27.84 is shown.
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Figure 5.2 The effect of incubation on ICAM-1 (CD54) expression
on human monocytes
Legend ICAM-1 expression (CD54) on isolated monocytes at 0 hours (blue), 4hours 
(yellow) and 24 hours (red) incubation in the absence of thrombin. Increasing mean 
fluorescence intensity is shown on the x axis.
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Figure 5.3 Monocyte ICAM-1 expression; effect of incubation with
human alpha thrombin
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Legend The change in ICAM-1 expression (antibody binding capacity-ABC) with time in 
the absence of thrombin (solid line), with 6.25 iu/300ul human alpha thrombin (dot and 
dash line) and 25 iu/300ul of thrombin (dotted line) Is shown.
Figure 5.4 The dose response relationship between thrombin
and monocyte ICAM-1
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Legend The change in ICAM-1 expression (ABC) with increasing concentrations 
of human alpha thrombin with mean values and interquartile ranges at each 
concentration is shown.
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Chapter 6
The relationship of the APCiSR in pregnancy with monocyte ICAM-1 
expression and plasma soluble ICAM-1
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6.1 Both pregnancy[127, 134, 233] and the APCR of pregnancy (Chapter 3) are 
associated with an Increase in thrombin generation. Furthermore oestrogen 
may modify cellular ICAM-1 expression[252]. In this study the relationship of 
monocyte ICAM-1 to pregnancy and to pregnancy-associated APCR was 
examined ex vivo. A relationship between APC:SR and monocyte ICAM-1 
would be compatible with the link between monocyte ICAM-1 expression and 
thrombin generation in vivo and a link between the APCR of pregnancy and 
adhesion molecule expression/inflammation. Furthermore, as in vitro studies 
suggest that an increase in cellular ICAM-1 expression is associated with an 
increase in shedding of ICAM-1 from the cell surface[40, 50-52], the study 
also determined whether there is a relationship between monocyte ICAM-1 
expression and plasma soluble ICAM-1 ex vivo.
6.2 Materials and Methods
6.2.1 Subjects
In a prospective study, 149 healthy pregnant subjects (age: mean 30 years, 
range 20-40 years) were recruited. All subjects had uncomplicated 
pregnancies. 60 were primigravid and 48 were smokers. Subjects were 
sampled at 8-15 weeks (n=27), 16-28 weeks (n=58), 29-34 weeks (n=47) 
and 35-40 weeks gestation (n=21). In addition 18 healthy, non-smoking, 
non-oral contraceptive using, female subjects (mean age 30 years, range 25- 
39 years) and 10 healthy non-smoking male subjects (mean age 30 years,
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range 25-39 years) were recruited. Institutional ethical approval was 
obtained and each individual was sampled on a single occasion.
6.2.2 Sample preparation
Samples were obtained by venepuncture from the antecubital vein and 
anticoagulated in 1/10 volume of 0.105 M sodium citrate. Samples for ex 
vivo assessment of monocyte ICAM-1 were stored at 4°C for less than 24 
hours before flow cytometric analysis. Samples for soluble plasma ICAM-1 
and APC:SR assessment were stored at ambient temperature for less than 
one hour, prior to double centrifugation at 3000G for 12 minutes. The 
resultant platelet poor plasma was stored at -70°C until analysis. APC:SR 
was assessed as detailed in Chapter 2. Plasma soluble ICAM-1 levels were 
determined by ELISA (R+D Systems Ltd, UK).
6.2.3 Flow cytometric analysis for ex-vivo ICAM-1 expression 
Sample Preparation
Monocytes in whole blood were identified by antiCD14 and monoclonal 
antibodies against CD54 (ICAM-1[244]) were used to quantify ICAM-1 on the 
monocyte surface. Whole blood preparations were stained using anti-CD14 
PE (Becton Dickinson Ltd, UK) and anti-CD54 FITC (Dako Ltd, UK). The
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subsequent sample preparation was as described in Chapter 5 aside from 
substitution of PBS-AB with PBS alone.
Analysis and quantification
Samples were acquired on a Facscan Flow Cytometer (Becton Dickinson Ltd, 
UK) using Lysis I I  software with a logarithmic amplification of the FLl and 
FL2 signals as used in Chapter 5. The monocytes were then analysed to 
determine the mean fluorescence intensity (MFI) of CD54 on the monocyte 
population. The CD54 MFI was then converted into antibody binding capacity 
(ABC) as before.
6.2.4 Statistical Analysis
ANOVA of groups, linear regression analysis of monocyte ICAM-1 with plasma 
ICAM-1, APC:SR and gestation and two sample t test comparisons of smoking 
and parity were carried out using Mlnitab®for Windows® Release 11 statistical 
software (Minitab Inc, USA).
6.3 Results
6.3.1 No significant difference in monocyte ICAM-1 ABC between males (mean 
14,979, SD 2049) and non-oral contraceptive (COCP) using female (mean 
15,554 ABC, SD 1652, F=0.62, p-0.44) was observed (Figure 6.1). A
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significantly higher level of monocyte ICAM-1 ABC was observed in pregnant 
subjects (mean 18,381, SD 4,499) in comparison with both male and non- 
COCP female subjects (F==5.91, p=0.003. Figure 6.1 and Table 6.1). This 
difference in expression is equivalent to the difference in mean fluorescence 
intensity of ICAM-1 which is observed when patients with a myocardial 
infarction are compared with non-myocardial infarction controls[253]. No 
significant relationship between ICAM-1 ABC and weeks of gestation 
(R^=0.0%, p>0.05) was observed. No significant difference in monocyte 
ICAM-1 ABC in comparison of primigravid vs parous subjects (t=-0.20, 
p>0.05) or smoking vs non-smoking subjects (t=0.90, p>0.05) was observed 
(Table 6.1).
6.3.2 No significant difference in plasma ICAM-1 was observed between male 
(mean 10.9 ug/ml, SD 2.9), non-OCP females (mean 9.2 ug/ml, SD 2.1) and 
pregnant subjects (mean 10.6 uig/ml, SD 3.2, F=1.61, p~0.2. Table 6.1). No 
significant relationship between gestation (linear regression R^=0.0%, 
p>0.05) or parity (t=1.97, p>0.05) and plasma ICAM-1 was observed. In 
pregnancy, a significantly higher level of soluble ICAM-1 was observed in 
smokers (mean 12.2qg/ml, SD 3.95) than non-smokers (mean 9.74qg/ml, 
SD 2.46, t=3.31, p=0.002. Table 6.1).
6.3.3 In pregnant subjects linear regression analysis revealed a significant positive 
relationship between monocyte ICAM-1 ABC and plasma ICAM-1 (Figure 6.2, 
R^  12.1%, p <0.0001). This relationship persisted when smokers were 
removed from the analysis (R^  12.0%, p=0.002). No significant relationship 
was demonstrated in non-pregnant women or men. A small but significant
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inverse relationship between monocyte ICAM-1 (R^  3.9%, p=0.05) and 
plasma ICAM-1(R  ^4.4%, p=0.03) with APC:SR at 28-32 weeks gestation was 
observed (Figures 6.3 and 6.4).
6.4 Discussion
6.4.1 In pregnancy, a condition characterised by a physiological increase in 
thrombin generation[127, 134, 233], an increase in the expression of 
monocyte ICAM-1 and a relationship between expression and the plasma 
level of its soluble form was observed. This suggests that soluble ICAM-1 
levels in pregnancy reflect monocyte expression and is consistent with the in- 
vitro experiments, which show that up-regulation of ICAM-1 is accompanied 
by an increase in shedding of soluble ICAM-1 from stimulated cells[40, 50- 
52]. Smoking in pregnant subjects appears to contribute to higher plasma 
levels of ICAM-1, but is not associated with higher monocyte ICAM-1 levels. 
Smoking may increase plasma ICAM-1 by cleavage of ICAM-1 from the 
monocyte surface, or by stimulation of expression of ICAM-1 on cells other 
than monocytes. The lack of an effect on monocyte ICAM-1 expression 
would be consistent with the published evidence on the protective effect of 
smoking on thrombin generation and pre-eclampsia detailed in Chapter 4.
6.4.2 No correlation of monocyte ICAM-1 expression with gestation after 7 weeks 
was observed. Although other studies[133, 134] have reported a correlation 
between Fl+2 and gestation, elevated levels of Fl+2 are a common feature 
of early normal pregnancy[134, 233]. In addition, TAT complex levels are
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reported to be elevated in the first trimester of 50% of normal 
pregnancies[127]. Thus the results presented here may be consistent with 
an increased sensitivity of monocytes to thrombin or to a combined up- 
regulating effect of increasing thrombin, cytokines and oestrogen[252] on 
monocyte ICAM-1 expression in pregnancy.
6.4.3 A significant negative relationship was observed between APC:SR at 28-32 
weeks gestation and both monocyte and soluble ICAM-1 at that gestation. 
This would be compatible with the negative correlation between APC:SR and 
thrombin generation observed in Chapter 3 and would suggest that ICAM-1 
expression in pregnancy is influenced by thrombin generation in vivo. 
Furthermore the relationship of APC:SR with monocyte ICAM-1 suggests that 
a lower APC:SR in pregnancy occurs along with an upregulation of the 
antigen presenting function of the monocyte.
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Table 6.1 The relationship between monocyte and plasma ICAM-1 
with sex  ^pregnancy and smoking
Monocyte ICAM-1 (ABC) Plasma ICAM-1 
(ug/m l)
Mean SD P Mean SD P
Males 1 4 ,9 7 9 2 ,0 4 9
0 .4 2
1 0 .9 2 .9
0 .3
Females 1 5 ,5 5 4 1 ,6 5 2 9 .2 2 .1
Pregnancy 1 8 ,3 8 1 4 ,4 9 9 0.003* 10 .6 3 .2 0.2^
Primigravid 1 8 ,4 2 3 4 ,2 7 9
0.68
9 .7 2 .6
0 .0 9
Parous 1 8 ,1 0 4 4,555 1 0 .7 3 .1
Smoking 1 8 ,6 9 1 3,756
0.37
1 2 .2 3 .9
0.002^
Non-smoking 1 8 ,0 1 3 4,270 9 .7 2 .5
Legend The mean and SD monocyte ICAM-1 (ABC) and plasma ICAM-1 (ug/ml) for 
males, females, all pregnant subjects (pregnancy), primigravid pregnant subjects, parous 
pregnant subjects, smoking and non-smoking pregnant subjects is shown. P values for 
ANOVA and t  test for comparisons of males and females, pregnant vs non-pregnant 
females (*p  significant at 0.003), primigravid vs parous women and pregnant smokers vs 
non-smokers (^ p significant at 0.002) is shown.
114
Figure 6.1 Monocyte ICAM-1 (ABC) in males, females 
and in pregnancy
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Legend The median and upper and lower interquartile range of ICAM-1 (ABC) 
for males, females and pregnant subjects is shown.
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Figure 6.2 Monocyte ICAM-1 vs plasma ICAM-1 in pregnancy
15000 20000
Monocyte ICAM-1 (ABC)
Legend Monocyte ICAM-1 expression (ABC) vs plasma ICAM-1 levels (ng/ml) 
In pregnancy. For guidance a linear regression line Is shown.
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Figure 6.3 APC:SR at 28-32 weeks gestation 
vs monocyte ICAM-1
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Legend Monocyte ICAM-1 expression (ABC) vs APC:SR at 28-32 
weeks gestation. For guidance a linear regression line is shown.
Figure 6.4 APC:SR at 28-32 weeks gestation 
vs plasma ICAM-1
♦ « »7.. ♦ $
Soluble ICAM -1 (ng/ml)
Legend Plasma ICAM-1 levels (ng/ml) vs APC:SR at 28-32 weeks gestation. 
For guidance a linear regression line is shown.
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Chapter 7
Conclusions
118
7.1 FVL, the principal inherited cause of APCR, has been linked to the failure of 
pregnancy with an increased risk of venous thrombosis[254], fetal loss[148] 
and pre-eclampsia[186]. Both venous thrombosis and pre-eclampsia are 
associated with inflammation. In particular pre-eclampsia is associated with 
a monocyte/macrophage Infiltration of the placental bed[154, 155]. That 
APCR, without FVLy (acquired APCR) may be a marker of thrombotic potential 
out-with pregnancy has been suggested by Rosing et al[98] and more 
recently by de Visser et al[238].
7.2 Changes In sensitivity to APC (assessed by the APC:SR) occur in normal 
pregnancy[76]. The aetiology and significance of this phenomenon has not 
been fully characterised. In this thesis, the pattern of change In APC:SR in 
pregnancy was detailed in FVL negative subjects. The relationship of the 
APC:SR to other coagulation factors and thrombin generation was 
investigated. The significance of the APC:SR to the mother and the fetus 
was also examined. To Investigate if a link (via thrombin) exists between the 
APC:SR and the inflammatory response, the inflammatory marker ICAM-1 
was examined on the monocyte. The influence of thrombin on the 
expression of this marker was examined in vitro and the relationship between 
the APC:SR in pregnancy and ICAM-1 was examined ex vivo.
7.3 In a large prospective study, the APC:SR at 7-15 weeks gestation showed a 
significant relationship with blood group and smoking, with higher APC:SRs 
observed in non-smokers and blood group 0 subjects. No significant 
relationship of APC:SR with body mass index, waist circumference, age, 
alcohol consumption, or family history of venous thrombosis or pregnancy-
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induced hypertension in a first degree relative was observed. In '^75% of 
pregnancies, a fall in APC:SR with increasing gestation was seen. Those who 
showed a fall in APC:SR (i.e. an increase in APCR) with increasing gestation 
had higher absolute APC:SR values at 7-15 weeks gestation than those who 
did not show a fall. APC:SR values less than the reference range observed in 
non-pregnant females were seen in 38% of subjects in the third trimester of 
pregnancy (28 to 40 weeks gestation) in the absence of FVL or elevated 
ACAs. In subjects without elevated ACAs or FVL, the APC:SR showed a 
significant negative relationship with factor VIIIc, factor Vc, and a positive 
relationship with free protein S. The relationship to factor VIIIc is compatible 
with the association of APCR and inflammatory disorders[83] and with the 
association of non-blood group 0, higher factor VIIIc levels and venous 
thrombosis[85-87]. The relationship with factor Vc is consistent with in vitro 
evidence that the APC:SR may be affected by factor Vc[213]. A significant 
contribution of protein S alone to the APC:SR may also occur.
7.4 The fall in APC:SR with gestation paralleled the fall observed in the red cell 
count, haemoglobin and mean red cell volume. This appeared to be due to 
the effect of gestation on both, rather than an effect of the APC:SR on the 
blood count. In the study by Lindqvist et al[205] it was suggested that 
heterozygous carriage of FVL results in a reduction In blood loss at delivery. 
In that study the assessment of blood loss was highly subjective. In a small 
group of FVL positive subjects (n=37) (Chapter 4) no difference in pre-natal, 
peri-natal, or post-natal blood loss was observed when compared with FVL 
negative subjects. Similarly, in FVL negative subjects, no relationship
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between pre-natal, peri-natal, or post-natal blood loss and APC:SR was 
observed.
7.5 No significant relationship between the APC:SR and placental weight was 
observed, although in subjects with an APC:SR less than the reference range 
for non-pregnant females, smaller birth weights were noted. When birth 
weights were corrected by adjustment for parity, gestation at delivery and 
fetal sex[231], and the influence of gestation on the APC:SR was minimised, 
no relationship between the APC:SR and birth weight was found. However 
significantly smaller birth weight centiles were observed in subjects in whom 
a fall in APC:SR with gestation occurred.
7.6 Significantly lower APC:SRs at 7-15 weeks were observed in subjects, 
normotensive at recruitment and with no past history of hypertension, who 
subsequently developed PIN or PET in the current pregnancy. This difference 
persisted for PIN when the analysis was restricted to primigravid subjects. 
No relationship between the APC:SR at 27-34 weeks gestation and the 
occurrence of PIN or PET was noted. A 2 fold (C.I.95 1.1-3.6) increased risk 
of PIN and 3 fold increased risk of PET (C.I.95 1.2-8.0) in the current 
pregnancy was observed In those subjects in whom no decrease in APC:SR 
was seen when compared with those in whom the APC:SR did decrease from 
7-15 to 27-34 weeks. These results suggest that, in the absence of FVL, 
subjects with a lower APC:SR early in pregnancy do not increase resistance 
to APC with increasing gestation and are at a higher risk of development of 
PIN and PET. They also appear to have larger babies than those in whom an 
increase in APCR occurs. As lower APC:SRs are associated with venous
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thrombosis[238], and as a decrease in the APC:SR occurs in the majority of 
pregnancies, this suggests that a higher APC:SR early in pregnancy and a fall 
in APC:SR with increasing gestation is a physiological response which mirrors 
fetal development. Individuals with a lower APC:SR early in pregnancy, do 
not become more resistant with increasing gestation and the (physiological) 
change in APC:SR does not occur. The response to APC appears to be set 
early in pregnancy and the sensitivity to APC may influence, or be influenced 
by, fetal development. The APC:SR, in the absence of FVL, does not, 
however, appear to predict fetal loss or neonatal death.
7.7 A significant inverse relationship between Fl+2 levels and APC:SR was 
observed, although this may reflect the influence of gestation on both 
variables. When the effect of increasing gestation was excluded, a significant 
inverse relationship between APC:SR and TAT concentration was observed at 
28-32 weeks, suggesting that the APC:SR may reflect thrombin generation in 
vivo.
7.8 Monocyte ICAM-1 expression, as assessed by flow cytometry, was influenced 
in a specific dose-dependent fashion by human alpha thrombin and may 
therefore be a useful indicator of the link between the coagulation cascade, 
thrombin and the inflammatory response of this cell. In pregnancy, a 
significantly higher level of monocyte ICAM-1 was observed when compared 
with non-COCP using female subjects. No significant relationship between 
ICAM-1 and gestation, parity or smoking was observed. In pregnant 
subjects, a significant positive relationship between monocyte ICAM-1 and 
plasma ICAM-1 was observed. This relationship was independent of
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smoking. A small but significant inverse relationship of both monocyte ICAM- 
1 and plasma ICAM-1 with APC:SR at 28-32 weeks gestation was noted. This 
suggests that in individuals with a normal pregnancy outcome the thrombin 
generation associated with the APC:SR at 28-32 weeks gestation is mirrored 
by the inflammatory response of the monocyte. However, as the monocyte 
has a significant, independent role in the activation of coagulation, it Is 
conceivable that activated monocytes could also influence the sensitivity to 
APC in plasma by modulating the generation of factor Villa and factor Va,
7.9 Although the APC:SR early in pregnancy predicts the occurrence of PIH and 
PET, the APC:SR assessed at 27-34 weeks appears insensitive to these 
disorders. Further study would be required to show if clinically evident PIH 
or PET is associated with an alteration of monocyte ICAM-1 expression. 
Furthermore, assessment of the relationship of monocyte ICAM-1 with 
markers of thrombin generation such as TAT would allow the link between 
the APC:SR and monocyte ICAM-1 to be confirmed as being due to thrombin 
generation in vivo.
7.10 Alteration of the balance of coagulation factors and inhibitors is a 
physiological response to pregnancy. The principal outcomes of the 
coagulation cascade include thrombin generation and fibrin formation. As 
shown here, increasing gestation is associated with an Increase in thrombin 
formation. Although thrombin can have an anticoagulant effect via protein C 
activation and is rapidly inhibited by alphaz macroglobulin[135], pregnancy is 
associated with an increased risk of ante-partum deep venous 
thrombosis[254]. This increased risk suggests that the thrombin generation
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of pregnancy is associated with a hypercoaguiable state which is 
compensated in the majority of subjects. In those subjects with heritable 
thrombophilia (such as FVL), this compensation may not occur and venous 
thrombosis[255], PET[186] and fetal loss[148] will result. An increase in 
thrombin generation, due to an increase in coagulation factors (including 
FVIIIc and FVc) occurs with increasing gestation and is likely to be a 
preparation for the haemostatic challenge of delivery. This is mirrored by the 
increase in ACPR with gestation which occurs in ~75% of pregnancies.
In addition to thrombin, fibrin formation appears to be integral to successful 
placental development[137] and has been shown to be important in chorionic 
villous repair[256]. The placenta is a significant source of tissue factor[257] 
and can also modulate the coagulation cascade via thrombomodulin[258]. It 
is likely then that the placenta is the driving force behind the increased 
thrombin generation observed in normal pregnancy. The aetiology of pre­
eclampsia is unknown, but is assumed to be due to an immunological 
response to the developing pregnancy. This results in abnormal trophoblast 
invasion of the developing placental bed. A process which is normally 
complete by 20 weeks gestation (reviewed in[259]). In pre-eclampsia it is 
conceivable that the reported alterations in maternal lipids, maternal 
coagulation (including an increase in tissue factor[260]) and the increase in 
inflammation, are a response to the pathological process in the developing 
placenta.
In normal pregnancy a relationship between the APC:SR, thrombin 
generation and the inflammatory response of the monocyte is seen. Whether
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pregnancies complicated by pre-eclampsia show an exaggerated monocyte 
ICAM-1 response requires further investigation. The potential interactions 
between these factors and the placenta are shown in Figure 7.1. In 25% of 
pregnancies the physiological Increase in ACPR with gestation does not occur. 
In these individuals a lower APC:SR is observed between 7 and 15 weeks 
gestation. Thus a relationship between the APC:SR (assessed at 7-15 weeks 
gestation) and the occurrence of pre-eclampsia exists before pre-eclampsia 
would be evident pathologically in the placenta. This indicates that the 
APC:SR is either a sensitive measure of the maternal response to early pre­
eclampsia, or that the APC:SR represents a phenotype (a combination of 
FVIIIc, FVc, PS, blood group, smoking and inflammation) which, like FVL, 
increases the susceptibility to the condition. This would be consistent with 
the observation that a low APC:SR, in the absence of FVL, is associated with 
venous thrombosis[238] and would also be consistent with the increased risk 
of VTE observed when FVL positive subjects are exposed to acquired APCR 
via the combined oral contraceptive[91] or pregnancy[254]. Peri-conceptual 
studies would be required to show how early in pregnancy the response to 
APC is set and would assist in refining the understanding of the maternal and 
fetal contribution to PET.
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Figure 7.1 The interaction between thrombin, the monocyte
and APCR
ENDOTHEUUM
TM/EPCR
aPC
THROMBINPLACENTAL
VASCULATURE M o n o c y teINFLAMMATION
FV
APCR
Inflammation 
Blood Group 
Factor V Leiden
Legend The interaction of the placenta with thrombin and maternal coagulation is 
shown. The function of TM and EPCR is altered by inflammation. TM = thrombomodulin, 
EPCR is the endothelial protein C receptor.
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